Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CBRX 2.32 Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Columbia Receives IRB Approval to Begin Enrolling Phase II Clinical Trial in Dysmenorrhea
Jun 27, 2007 7:30:00 AM
Copyright Business Wire 2007
LIVINGSTON, N.J.--(BUSINESS WIRE)--
Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced positive results from a recently-completed multi-dose pharmacokinetic study of vaginally-administered lidocaine, which the Company is developing to prevent and treat dysmenorrhea.
This 42-subject study was designed to provide data on blood levels associated with the Company's bioadhesive vaginal lidocaine formulation at three dose strengths over multiple doses. The cohort was randomly divided into three groups, which corresponded to the three different dose strengths of the lidocaine product candidate.
"For each of the dose levels studied, use of our bioadhesive vaginal lidocaine formulation over four consecutive days was associated with blood levels that are well within an accepted range," stated George Creasy, M.D., FACOG, Columbia's vice president of clinical research and development. "At the highest dose, those blood levels are what we anticipated based on extrapolation of data from the prior, single-administration pharmacokinetic study. This indicates a positive safety profile for our lidocaine product candidate relative to the known systemic effects of lidocaine."
"This positive data strengthens our resolve to speed the path to market for our lidocaine product. We received approval from the Institutional Review Board to conduct a Phase II cross-over study with this drug candidate and we will begin recruiting patients in this study very soon," stated Robert S. Mills, president and chief executive officer of Columbia Laboratories. "There are approximately 5.6 million women who suffer from the painful menstrual cramping that characterizes dysmenorrhea, which limits their normal activities and causes them to lose time from school or work. We believe our lidocaine product can fill a real unmet medical need and improve the lives of these women, assuming positive data in current and future clinical studies."
About Dysmenorrhea
Dysmenorrhea is characterized by recurrent uterine cramping and pain before and during menses. This common, painful women's health condition seriously affects 12% of all menstruating women in the U.S. between the ages of 20 and 45, or about 5.6 million women. It is estimated to account for 600 million lost work hours and approximately $2 billion in lost productivity annually. Current treatments address the pain but not the underlying problem. Columbia's hypothesis is that administering lidocaine vaginally, using its proprietary bioadhesive delivery system (BDS) technology, can minimize or prevent the severe cramping that results in the debilitating pain of dysmenorrhea.
About Columbia Laboratories
Columbia Laboratories, Inc. is a is a specialty pharmaceutical company focused on developing and marketing products for the women's healthcare and endocrinology markets using its novel bioadhesive drug delivery technology. Columbia markets CRINONE(R) 8% (progesterone gel) and PROCHIEVE(R) 8% (progesterone gel) in the United States for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency and PROCHIEVE 4% (progesterone gel) for the treatment of secondary amenorrhea. The Company also markets STRIANT(R) (testosterone buccal system) for the treatment of hypogonadism in men. For more information, please visit www.columbialabs.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements about Columbia Laboratories, Inc.'s expectations regarding the Company's strategic direction, prospects and future results, and clinical research programs, which statements are indicated by the words "will," "plan," "expect" and similar expressions. Such forward-looking statements are subject to certain risks and uncertainties; actual results may differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the following: the successful marketing of CRINONE(R) 8% (progesterone gel), PROCHIEVE(R) 8% (progesterone gel), PROCHIEVE 4% (progesterone gel), and STRIANT(R) (testosterone buccal system) in the U.S.; the timely and successful development of new products, including determining the clinical and regulatory path for possible development of PROCHIEVE 8% for the prevention of preterm birth; the timely and successful completion of clinical studies, including the clinical studies for our vaginally-administered lidocaine product candidate; success in obtaining acceptance and approval of new products and new indications for current products by the FDA and international regulatory agencies, the impact of competitive products and pricing; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission. Columbia Laboratories undertakes no obligation to publicly update any forward-looking statements.
CRINONE(R), PROCHIEVE(R) and STRIANT(R) are registered trademarks of Columbia Laboratories, Inc.
Source: Columbia Laboratories, Inc.
----------------------------------------------
Columbia Laboratories
Inc.
James A. Meer
973-486-8860
Senior Vice President
CFO & Treasurer
or
Rx Communications Group
LLC
Melody A. Carey
917-322-2571
Co-President
SMD .64 Tony Handal Named CEO of The Singing Machine Company
Jun 27, 2007 7:30:00 AM
Copyright Business Wire 2007
COCONUT CREEK, Fla.--(BUSINESS WIRE)--
The Singing Machine Company, Inc. (AMEX:SMD) today announced the appointment of Anton "Tony" Handal as the Chief Executive Officer of the Company. Former interim CEO and current Chief Financial Officer Danny Zheng will remain as the CFO of the Company.
"Tony Handal has, for many years, been a close and trusted advisor to Starlight International Holdings Ltd., our majority shareholder, as well as to other Asian manufacturers of consumer electronics products. He was instrumental in Starlight's acquisition of its stake in The Singing Machine and has significant merger and acquisition experience. An expert in product licensing, Tony also brings outstanding experience and contacts in consumer electronics distribution to his new role at The Singing Machine. He has counseled major U.S. consumer electronics retailers on a variety of issues affecting our business. We expect Tony's depth of directly relevant experience and his extensive network of industry contacts to be invaluable in the successful implementation of the Company's strategic expansion plan," said Carol Lau, Chairman.
"We also want to thank Danny Zheng for his outstanding performance as both Interim CEO and CFO during the past few months. We are confident that Danny and Tony will make an excellent team and provide strong, aggressive leadership for The Singing Machine," the Chairman added.
Mr. Handal, 52 years old, is a principal of Handal & Associates, which specializes in corporate and securities law, mergers and acquisitions, and regulatory affairs. He founded Handal & Associates in 1983.
About The Singing Machine
Incorporated in 1982, The Singing Machine Company develops and distributes a full line of consumer-oriented karaoke machines and music as well as other electronic products under The Singing Machine(TM), Motown(TM), MTV(TM), Nickelodeon(TM), Hi-5(TM), Bratz(TM) and other brand names. The first to provide karaoke systems for home entertainment in the United States, The Singing Machine sells its products in North America, Europe and Asia.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors. In addition, you should review our risk factors in our SEC filings which are incorporated herein by reference. Such forward-looking statements speak only as of the date on which they are made and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release.
Source: The Singing Machine Company, Inc.
----------------------------------------------
The Singing Machine Company
Inc.
Danny Zheng
CFO
954-596-1000
www.SingingMachine.com
or
Investor Contact:
Berkman Associates
Neil Berkman
310-826-5051
info@BerkmanAssociates.com
YMI 1.82 YM BioSciences Receives FDA Clearance for an IND for its Fentanyl-Based Pain Product AeroLEF(TM)
- YM to initiate trial in the U.S. and plans End of Phase II meeting with FDA -
Jun 27, 2007 7:00:00 AM
MISSISSAUGA, ON, June 27 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AeroLEF(TM).
AeroLEF(TM) is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. In contrast to fixed-dose approaches to opioid delivery, where a significant titration period is often required to determine the suitable dose for the patient, AeroLEF(TM) is being developed as a non-invasive delivery system designed to enable patients to self-titrate. Using AeroLEF(TM), patients can identify and select a personalized dose for each pain episode, achieving both rapid onset and extended duration of analgesia.
"This clearance marks the start of a formal path towards regulatory approval for AeroLEF(TM) in the U.S. and builds on the momentum of having recently reported positive Phase II data for this unique and important product," said David Allan, Chairman and CEO of YM BioSciences. "Under this IND, YM plans to initiate an open-label Phase II trial designed to expand the target patient population of AeroLEF(TM) and in parallel is planning an End of Phase II meeting with the FDA to gain agreement on the design of the Phase III program. The Phase II study is planned to recruit up to 50 post-surgical patients across three sites in the U.S. and will include a number of opioid tolerant patients to evaluate AeroLEF(TM) in this increasingly important market segment."
YM recently reported that AeroLEF(TM) met its primary endpoint in a 99 patient, randomized, placebo-controlled, multi-center Phase IIb trial (DLXLEF-AP4) in opioid-naive patients with post-operative pain following orthopedic surgery. AeroLEF(TM) showed a statistically significant difference in SPRID4 (a summary of the combined changes in pain relief and in pain intensity that patients report over the first four hours following initiation of dosing) from placebo for the treatment of the first pain episode (p=0.0194). YM is completing a detailed analysis of the numerous secondary endpoints and safety data from this study to extend the information it will make available.
About YM BioSciences
YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company is advancing two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.
This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(TM) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE YM BioSciences Inc.
----------------------------------------------
Thomas Fechtner
the Trout Group LLC
Tel. (212) 477-9007 x31
Fax (212) 460-9028
Email: tfechtner@troutgroup.com; James Smith
the Equicom Group Inc.
Tel. (416) 815-0700 x 229
Fax (416) 815-0080
Email: jsmith@equicomgroup.com
BDAY 8.76 Birthday Express Scores With Disney's High School Musical and Hannah Montana
Website and catalog offer complete party supplies from themed banners to party favors
Jun 27, 2007 7:00:00 AM
KIRKLAND, Wash., June 27 /PRNewswire-FirstCall/ -- Crank up the volume and get set for a rocking good time. Birthday Express has all the birthday party supplies parents need to wow a child crazy about Disney's High School Musical and Hannah Montana, Disney Channel's hugely popular programs that have become a pop culture phenomenon.
Birthday Express, the leading web and catalog party supplies retailer, makes it easy for parents to transform their child's birthday party into a Hollywood-style celebration with their favorite musical stars. Offering more than 150 birthday party themes, Birthday Express provides the complete solution for busy parents by assembling everything needed to throw a birthday party -- colorful themed paper products, party favors, pinatas, craft activities, and even party-planning ideas.
High School Musical and Hannah Montana top the charts among the many licensed characters found at Birthday Express, which sells direct through its catalogs and website at http://www.celebrateexpress.com. Here's a sampling of the hard-to-find party goods sure to make your music-lover's party a hit:
-- High School Musical -- Paper party goods and fun decorations capture
all the thrills of auditions and cheering for the Wildcats from this
Emmy award-winning television musical. A customer favorite is a
coordinating banner with free personalization ($14.99). This heavy-
duty vinyl banner with grommets works for parties both indoor and
outdoor. Customized message and child's name are added free of charge.
-- Hannah Montana -- A favorite with the tween set, Hannah Montana party
supplies capture the energy of the popular teen who lives a secret life
as a world-famous pop star. Hannah rocks with themed birthday party
goods and a full assortment of crafts to keep the party hopping.
Customer favorites include a personalized banner, pinata and Hannah
Montana CD ($18.99) -- Excellent background music for the party from
and inspired by the hit TV series.
Party planning tips are available for these themes and more at http://www.celebrateexpress.com.
About Birthday Express
Since its debut in 1994, Birthday Express has been known for its extensive selection of children's party supplies, offering more than 150 birthday party themes with 40 proprietary themes created by its own designers. Birthday Express is a brand operated by Celebrate Express, Inc. (Nasdaq: BDAY), a leading supplier of celebration products for families. Complete themed party solutions are offered in branded catalogs and online at http://www.celebrateexpress.com for three brands: Birthday Express; 1st Wishes, featuring first birthday party supplies; and Costume Express, offering more than 550 costumes.
SOURCE Birthday Express
----------------------------------------------
Therese Beale
+1-425-827-4121
tbeale@bealecommunications.com
for Birthday Express
ECI 3.47 Encision to Manufacture Its Own Disposable Scissor Inserts
Jun 27, 2007 7:00:00 AM
BOULDER, Colo., June 27 /PRNewswire-FirstCall/ -- Encision Inc. (Amex: ECI), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, announced that it will begin to manufacture its own disposable scissor inserts this summer.
"Sales of our disposable scissor inserts represent approximately 50% of our sales and we believe that we will be able to achieve a major cost reduction by producing our own disposable scissor inserts," said Jack Serino, President & CEO of Encision. "We also expect to provide better control over the quality and consistency of this significant product line. By owning the process and manufacturing expertise for our disposable scissor inserts, we believe that we will add intrinsic value to Encision."
"Last fiscal year, to accommodate the disposable scissor insert manufacturing, we expanded our facilities by leasing an additional 9,000 square feet of space adjacent to our present facility in Boulder. In May 2007, we entered into a lease for the manufacturing equipment. The manufacturing process is highly automated and will allow for significant volume increases without the need for significant headcount increases. Field evaluations comparing our present vendor-made disposable scissor inserts to Encision-made disposable scissor inserts have been successfully completed."
Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM(R) Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase revenues through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.
CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600,
mmchaffie@encision.com
SOURCE Encision Inc.
----------------------------------------------
Marcia McHaffie of Encision Inc.
+1-303-444-2600
mmchaffie@encision.com
SGMO 7.91 Sangamo BioSciences to Present at the Jefferies Healthcare Conference
Jun 27, 2007 7:00:00 AM
RICHMOND, Calif., June 27 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at the Jefferies Healthcare Conference in New York on Thursday, June 28, 2007 at 3:40 pm (ET).
The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF (TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN (TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and applications of Sangamo's ZFP TF technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.
SOURCE Sangamo BioSciences, Inc.
----------------------------------------------
Elizabeth Wolffe
Ph.D of Sangamo BioSciences
Inc.
+1-510-970-6000
ext. 271
ewolffe@sangamo.com; or Justin Jackson of Burns McClellan
Inc.
+1-212-213-0006
for Sangamo BioSciences
Inc.
GEE 4.84 Global Entertainment Subsidiary to Joint Venture Development of $50 Million Multi-Purpose Events Center for Allen, Texas
Jun 27, 2007 7:00:00 AM
Copyright Business Wire 2007
PHOENIX--(BUSINESS WIRE)--
Global Entertainment Corporation (AMEX: GEE), a company engaged in sports management, arena and related real estate development, facility and venue management and marketing, venue ticketing and brand licensing, announced today that its subsidiary company, Global Properties I, will be part of a joint venture to build a $50 million multi-purpose events center for the City of Allen, Texas, a northeast suburb of Dallas. A Letter of Intent was approved at a City Council meeting held yesterday that combines the expertise of Global Properties I, The MGHerring Group of Dallas and the City of Allen in a project to develop a state-of-the-art, multi-use entertainment facility for the citizens of Allen, Texas and the surrounding region. The facility will have 7,500 fixed seats as well as 24 luxury suites.
A multi-layered company, Global Entertainment (Global) provides a turnkey solution for developing, opening, managing and marketing multi-purpose facilities. In addition to Global Properties I, five other Global subsidiaries will serve a broad range of functions for the Allen project. International Coliseums Company will head design and construction. The Western Professional Hockey League d/b/a the Central Hockey League will award a new Double-A level franchise to serve as the center's primary tenant. Encore Facility Management will engage in a multi-year agreement to manage the building, along with its licensing and advertising arm, Global Entertainment Marketing Systems, which will handle all sales and marketing services. Finally, GetTix will provide exclusive ticketing services for all events in Allen's arena.
The new $50 million multi-purpose events center is anticipated to open in the Autumn 2009. The Allen Event Center will be part of The Village at Allen, a 181-acre mixed-use development of The MGHerring Group.
Steven J. Bielewicz, president of Global Properties I, said, "We look forward to working with The MGHerring Group and the City of Allen in developing a prime entertainment facility for the citizens of Allen and the community at large. We will draw on our past experience completing projects for communities similar to Allen to create a facility that is complementary to the overall mixed-use development that is planned for the community."
Richard Kozuback, president and chief executive officer of Global Entertainment Corporation, stated, "Winning approval for a new development project is an exciting event for all involved and we are pleased that our subsidiary, Global Properties I, is one party in the joint venture for the multi-purpose events center to be built in Allen, Texas. The development for Allen represents a perfect project model as it utilizes the full spectrum of our integrated businesses designed to capitalize on cross-revenue generation. We are currently in discussions with other municipalities for projects of a like nature in various parts of the U.S."
Visit our web sites:
www.globalentertainment2000.com www.centralhockeyleague.com
www.coliseums.com www.cragar.com www.gettix.net
Global Entertainment Corporation is an integrated events and entertainment company focused on mid-size communities that is engaged, through its seven wholly owned subsidiaries, in sports management, multi-purpose events and entertainment center and related real estate development, facility and venue management and marketing, venue ticketing and brand licensing. The Western Professional Hockey League, Inc., through a joint operating agreement with the Central Hockey League, is the operator and franchisor of professional minor league hockey teams in nine states. International Coliseums Company serves as project manager for arena development while Encore Facility Management coordinates all arena facility operations. Global Entertainment Marketing Systems (GEMS) pursues licensing and marketing opportunities related to the Company's sports management and arena developments and operations. Global Properties I in correlation with arena development projects works to maximize value and development potential of new properties. Global Entertainment Ticketing (GetTix.Net) is an in-house ticketing company for sports and entertainment venues. Cragar Industries, Inc. is the licensor for its nationally recognized, branded products CRAGAR(R), TRUSPOKE(R), CRAGAR S/S(R) and STREET PRO(R).
Certain statements in this release may be "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements may include projections of matters that affect revenue, operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.
Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.
Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: intense competition within the sports and entertainment industries, past and future acquisitions, expanding operations into new markets, risk of business interruption, management of rapid growth, need for additional financing, changing consumer demands, dependence on key personnel, sales and income tax uncertainty and increasing marketing, management, occupancy and other administrative costs.
These factors are discussed in greater detail in the company's Annual Report on Form 10-KSB for the year ended May 31, 2006, as filed with the Securities and Exchange Commission.
Source: Global Entertainment Corporation
----------------------------------------------
Global Entertainment Corporation
Richard Kozuback
480-994-0772
or
The Miller Group
Investor Relations
Rudy R. Miller
602-225-0505
gee@themillergroup.net
SUNW 5.06 Sun Microsystems to Conduct Q4 Fiscal 2007 Financial Results Conference Call on July 30, 2007
Jun 26, 2007 9:00:00 AM
SANTA CLARA, Calif., June 26 /PRNewswire-FirstCall/ -- Sun Microsystems, Inc. (Nasdaq: SUNW) will host its Q4 Fiscal 2007 financial results conference call on Monday, July 30, 2007, beginning at 1:30 p.m. PDT. The general public is welcome to listen to the call via Sun's Investor Relations website at http://www.sun.com/investors.
Sun periodically webcasts company announcements, product launch events and executive presentations via its website at http://www.sun.com/investors. Sun encourages investors to check this website frequently for updates. Investors can also receive updates directly by subscribing to Sun's syndicated content service. For more information about Sun's Investor Relations RSS Feeds, please visit http://www.sun.com/aboutsun/investor/rss.jsp. To subscribe to Sun's Newswire Service for email-based updates on the company's latest news, please visit http://www.sun.com/aboutsun/media.
About Sun Microsystems, Inc.
A singular vision -- "The Network Is The Computer" -- guides Sun in the development of technologies that power the world's most important markets. Sun's philosophy of sharing innovation and building communities is at the forefront of the next wave of computing: the Participation Age. Sun can be found in more than 100 countries and on the Web at http://www.sun.com.
Sun, Sun Microsystems, the Sun logo, Java, and The Network Is The Computer are trademarks or registered trademarks of Sun Microsystems, Inc. in the United States and other countries.
Investor Contact:
Bret Schaefer
650-786-0123
bret.schaefer@sun.com
Press Contact:
Kristi Rawlinson
650-786-6933
kristi.rawlinson@sun.com
SOURCE Sun Microsystems, Inc.
----------------------------------------------
Investors
Bret Schaefer
+1-650-786-0123
bret.schaefer@sun.com
or Press
Kristi Rawlinson
+1-650-786-6933
kristi.rawlinson@sun.com
both of Sun Microsystems
Inc.
CAPA 5.01 Luxury Hotel Company Takes the Next Step to Paperless With Captaris RightFax Solution
- Part of a total document management solution delivered by IKON Office Solutions
Jun 26, 2007 9:00:00 AM
BELLEVUE, Wash., and MALVERN, Pa., June 26 /PRNewswire-FirstCall/ -- Captaris, Inc. (Nasdaq: CAPA), a leading provider of software products that automate document-centric processes, and IKON Office Solutions (NYSE: IKN), the world's largest independent channel for document management systems and services, today announced that Rosen Hotels & Resorts has selected Captaris RightFax to provide networked fax services. The solution is integrated with Microsoft Exchange, Cisco CallManager and Canon multi-function peripherals (MFPs) to provide a central document management solution that has immediately improved the guest experience by increasing productivity and streamlining communications. Read the full case study at http://www.captaris.com/case_studies
Rosen Hotels & Resorts is the largest independent hotel company in Florida, operating seven luxury properties in the Orlando area and two subsidiaries: Provinsure, an insurance agency, and Millenium Technology Group (MTG), a networking company that provides telecommunications and IT services to the hospitality industry. Many different paper documents are shared among Rosen facilities including reservation confirmations and banquet event orders. Rosen also manages its own medical clinic for employees, dependents and students and the handling of their patient records must meet HIPAA privacy standards. When MTG developed the IT architecture for Shingle Creek (Rosen's new property that opened in 2006), the goal was to create a paperless environment with a centralized document management capability that could subsequently be extended throughout the Rosen organization.
At the recommendation of IKON, the company's partner that manages its business centers, Rosen installed Captaris RightFax at Shingle Creek and has since extended it to more than 870 end users in all seven hotels, the medical center and the insurance agency. "RightFax is the next step in the process for a paperless office due to its integration with Microsoft Exchange, Cisco CallManager, Canon MFPs and eCopy," says Jim Bina, MTG president and director of IT for Rosen. Central fax management automatically creates more legible files, supplies a reliable audit trail and creates easier access to documents and HIPAA compliance security for medical records.
"IKON was involved throughout the entire process of planning, project management and roll out," says Kevin Drinan, Rosen's convention technology manager. "Implementing a solution as large and complex as ours required a partner with an expert professional services team, which was evident with IKON. They were able to implement a seamless solution -- even working through the convergence of old and new systems -- and trained users on the new technology in only a week."
With RightFax, employees now send faxes from virtually any software application on the desktop or right from the MFPs. All tasks are completed without touching paper. Rosen also uses Microsoft SharePoint for collaboration and sharing documents. Faxes are filed into SharePoint, where they are readily accessed by various departments. All faxes are also remotely accessible because of the RightFax integration with Cisco CallManager. RightFax also supports a mobile workforce, providing immediate notification when important documents are received-a feature particularly useful to the events and catering staff who are often out of their offices. "Thousands of dollars are involved in servicing events," said Kevin Drinan, Rosen's convention technology manager. "With RightFax I receive immediate notification on my Blackberry, which allows us to implement work orders right away."
RightFax is now an integral component of Rosen's digital document management system. The paperless fax processes are saving money and time. The faster response to customer requests leads to a better guest experience. And the 870 employees who now use RightFax are enhancing their productivity by eliminating hours of fax-related paperwork every day.
About Captaris, Inc.
Captaris, Inc. is a leading provider of software products that automate business processes, manage documents electronically and provide efficient information delivery. Our product suite of Captaris RightFax, Captaris Workflow and Captaris Alchemy is distributed through a global network of leading technology partners. We have customers in financial services, healthcare, government and many other industries, and our products are installed in all of the Fortune 100 and many Global 2000 companies. Headquartered in Bellevue, Washington, Captaris was founded in 1982 and is publicly traded on the NASDAQ Global Market under the symbol CAPA. For more information, visit http://www.Captaris.com.
About IKON
IKON Office Solutions, Inc. (http://www.ikon.com) is the world's largest independent channel for document management systems and services, enabling customers worldwide to improve document workflow and increase efficiency. IKON integrates best-in-class copiers, printers and MFP technologies from leading manufacturers, such as Canon, Ricoh, Konica Minolta, Kyocera Mita and HP, and document management software and systems from companies like Captaris, Kofax, EFI, eCopy and others, to deliver tailored, high-value solutions implemented and supported by its global services organization -- IKON Enterprise Services. With fiscal year 2006 revenue of $4.2 billion, IKON has approximately 25,000 employees in over 400 locations throughout North America and Western Europe.
IKON Office Solutions(R) and IKON: Document Efficiency at Work(R) are trademarks of IKON Office Solutions, Inc. All other trademarks are the property of their respective owners.
The following are registered trademarks and trademarks of Captaris: Captaris, Alchemy, RightFax and Captaris Workflow. All other brand names and trademarks are the property of their respective owners.
SOURCE Captaris, Inc.
----------------------------------------------
Barrie Locke of Ripple Effect Communications
+1-585-377-1839
blocke@recommunication.com
for Captaris
Inc.; or Wendy Pinckney of IKON Office Solutions
+1-610-408-7297
wpinckney@ikon.com
OPTV 2.13 OpenTV Launches 'Rapid Porting Program'
Program to Focus on Faster Time to Market, Lower Porting Costs and Reduced Operational Expenses
Jun 26, 2007 9:00:00 AM
SAN FRANCISCO, June 26 /PRNewswire-FirstCall/ -- OpenTV Corp. (Nasdaq: OPTV), a leading provider of solutions for the delivery of advanced television and cross platform interactive services, today announced the introduction of its new Rapid Porting Program (RPP) to provide rapid, high quality ports of OpenTV middleware to a wide range of chipsets and set top boxes.
The goal of the Rapid Porting Program is to bring together the silicon vendors, set-top box (STB) manufacturers, conditional access suppliers, and systems integrators to create full-feature set-top boxes that can be brought to market quickly. By fostering the development of pre-integrated and pre- tested drivers between specific chipsets and OpenTV's Core2(TM) and PVR2(TM) solutions, the Rapid Porting Program will offer significant benefits to network operators.
According to Alan A. Guggenheim, OpenTV's President and CEO, "OpenTV's Rapid Porting Program promotes cooperation among the partners and fosters targeted sales and marketing efforts with our common customers and prospects. The benefits of RPP include bringing solutions to market faster, lowering porting costs, reducing operational expenses and achieving faster issue resolution. No one in the industry is approaching the problem in this way and the response to this new initiative by manufacturers and operators has been positive and gratifying."
The initial launch of the program is focused on efforts with chipset and set-top box manufacturer partners. The charter partners for the program include Broadcom, Conexant, and NXP Semiconductors as well as Philips Consumer Electronics. OpenTV expects other partners to join as the program advances.
"The OpenTV Rapid Porting Program will speed up the introduction of Philips new high definition (HD) set-top boxes and HD digital video recorders (DVRs) into the market," said Philippe Alcaras, Senior Vice President and General Manager of Home Networks at Philips Consumer Electronics. "This new program also delivers on Philips' brand promise of Sense and Simplicity as it will simplify the HD launch for Philips and OpenTV operators and provide high quality innovative solutions to our customers."
"OpenTV's Rapid Porting Program will enable us to meet our customers' desire for fully integrated hardware and software solutions that allow them to accelerate the delivery of complete products based on our advanced HD-AVC SoCs," said Lewis Brewster, senior vice president and general manager of Conexant's Broadband Media Processing business. "We're pleased to be one of the first chipset vendors to support this program, and providing our customers with even greater levels of service and support."
"With its advanced set-top box solutions, NXP Semiconductors is powering developments in the CE market. Our technology allows STB makers to deliver premier products to the market more quickly and at mass market price points. By partnering with OpenTV, NXP can continue to provide revolutionary offerings to the operator market-complete system solutions that boast both state-of-the-art hard and middleware," said Guus Frericks, VP and General Manager, NXP Semiconductors, Business Line Set-Top-Box and Home Media Devices.
"OpenTV's rapid porting program is an ideal way for Broadcom and OpenTV to enable our customers and minimize time-to-market across the industry's widest array of high-performance HD and SD AVC/VC-1 set-top platforms that we each offer," said John H. Gleiter, Senior Director of Marketing for Broadcom's set- top box platforms. "We are excited about working closely with OpenTV and offering this combined solution to the marketplace."
About OpenTV
OpenTV is one of the world's leading providers of solutions for the delivery of digital and interactive television. The company's software has been integrated in over 88 million digital set-top boxes and digital televisions around the world. The software enables enhanced program guides, video-on-demand, personal video recording, enhanced television, interactive shopping, interactive and addressable advertising, games and gaming and a variety of consumer care and communication applications. For more information, please visit http://www.opentv.com.
About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in healthcare, lifestyle and technology, delivering products, services and solutions through the brand promise of "sense and simplicity". Headquartered in the Netherlands, Philips employs approximately 121,700 employees in more than 60 countries worldwide. With sales of EUR 27 billion in 2006, the company is a market leader in medical diagnostic imaging and patient monitoring systems, energy efficient lighting solutions, personal care and home appliances, as well as consumer electronics. News from Philips is located at http://www.philips.com/newscenter.
About Conexant
Conexant's innovative semiconductor solutions are driving broadband communications and digital home networks worldwide. The company has leveraged its expertise and leadership position in modem technologies to enable more Internet connections than all of its competitors combined, and continues to develop highly integrated silicon solutions for broadband data and media processing networks. Key products include client-side xDSL and cable modem solutions, home network processors, broadcast video encoders and decoders, digital set-top box components and systems solutions, and dial-up modems. Conexant's suite of networking components includes a leadership portfolio of IEEE 802.11-compliant WLAN chipsets, software and reference designs, as well as solutions for applications based on HomePlug(R) and HomePNA(TM). The company also offers a complete line of asymmetric and symmetric DSL central office solutions, which are used by service providers worldwide to deliver broadband data, voice, and video over copper telephone lines.
Conexant is a fabless semiconductor company that recorded revenues of $970.8 million in fiscal year 2006. The company has approximately 3,200 employees worldwide, and is headquartered in Newport Beach, Calif. To learn more, please visit http://www.conexant.com.
About NXP
NXP is a top 10 semiconductor company founded by Philips more than 50 years ago. Headquartered in Europe, the company has 37,000 employees working in 26 countries across the world. NXP creates semiconductors, system solutions and software that deliver better sensory experiences in mobile phones, personal media players, TVs, set-top boxes, identification applications, cars and a wide range of other electronic devices. News from NXP is located at http://www.nxp.com.
About Broadcom
Broadcom Corporation is a major technology innovator and global leader in semiconductors for wired and wireless communications. Broadcom products enable the delivery of voice, video, data and multimedia to and throughout the home, the office and the mobile environment. We provide the industry's broadest portfolio of state-of-the-art, system-on-a-chip and software solutions to manufacturers of computing and networking equipment, digital entertainment and broadband access products, and mobile devices. These solutions support our core mission: Connecting everything(R).
Broadcom is one of the world's largest fabless semiconductor companies, with 2006 revenue of $3.67 billion, and holds over 2,000 U.S. and 800 foreign patents, more than 6,000 additional pending patent applications, and one of the broadest intellectual property portfolios addressing both wired and wireless transmission of voice, video and data.
Broadcom is headquartered in Irvine, Calif., and has offices and research facilities in North America, Asia and Europe. Broadcom may be contacted at +1.949.926.5000 or at http://www.broadcom.com.
Cautionary Language Regarding Forward-Looking Information
The foregoing information contains certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations due to changes in political, economic, business, competitive, market and regulatory factors. In particular, factors that could cause our actual results to differ include risks related to: market acceptance of interactive television services and applications such as ours; delays in the development or introduction of new applications and versions of our service; technical difficulties with networks or operating systems; our ability to manage our resources effectively; changes in technologies that affect the television industry; and the protection of our proprietary information. These and other risks are more fully described in our periodic reports and registration statements filed with the Securities and Exchange Commission and can be obtained online at the Commission's web site at http://www.sec.gov. Readers should consider the information contained in this release together with other publicly available information about our company for a more informed overview of our company. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE OpenTV Corp.
----------------------------------------------
Barbara Cassidy of OpenTV
+1-415-962-5000
bcassidy@opentv.com; or Lisa Ruiz Rogers of Manning
Selvage & Lee
+1-323-866-6059
lisa.rogers@mslpr.com
for OpenTV Corp.; or Natasha Konstantinova of Philips Consumer Electronics
+31 20 59 776 77
natasha.konstantinova@philips.com
CRTX 2.34 Critical Therapeutics' Zileuton Provides Additional Asthma Control When Combined with Inhaled Corticosteroids
Study Data Presented in Peer-Reviewed Journal Respiratory Medicine
Jun 26, 2007 9:00:00 AM
Copyright Business Wire 2007
LEXINGTON, Mass.--(BUSINESS WIRE)--
Critical Therapeutics, Inc. (Nasdaq: CRTX), a biopharmaceutical company focused on the development and commercialization of products for respiratory, inflammatory and critical care diseases, announced today the publication of a peer-reviewed article based on a study of zileuton, the Company's 5-lipoxygenase (5-LO) inhibitor. The study suggests that combining zileuton (400 or 600 mg QID) with a low-dose inhaled corticosteroid (ICS) improves pulmonary lung function and may be an effective therapeutic approach to achieving asthma control in patients with moderate to severe persistent disease.
The article, "Zileuton added to low-dose inhaled beclomethasone for treatment of moderate to severe persistent asthma", was published in the June issue of Respiratory Medicine. The lead author is Brian J. O'Connor, M.D. of King's College London School of Medicine.
Data presented in the article was based on a two-week, single-blind run-in period, followed by a 12-week randomized, active-controlled, multi-center study. A total of 320 patients qualified for the double-blind testing period and were randomized to three groups across 32 centers in Canada and Europe: zileuton 400 mg 4 times per day plus 400 mg beclomethasone dipropionate (BDP) twice daily (n=108); zileuton 600 mg 4 times per day plus 400 mg BDP twice daily (n=110); and placebo group plus 800 mg BDP twice daily (n=102).
The study was designed to assess the therapeutic effects of oral zileuton tablets combined with low-dose BDP, compared to doubling the dose of BDP, in improving lung function and reducing asthma symptoms. There were no clinically significant differences between treatment groups in the primary outcome of Forced Expiratory Volume in one second (FEV(1)), as all treatment groups improved. There were significant improvements in Peak Expiratory Flow (PEF) in the 400 and 600 mg zileuton groups, compared to baseline. The data suggests that the addition of zileuton to low-dose BDP may be an alternative to using higher doses of ICS in patients unable to achieve asthma control on a low-dose ICS therapy.
In this study, adverse events were similar across all groups. Five patients had alanine aminotransferase (ALT) values of greater than two times the upper limit of normal (greater than or equal to 2x ULN): four on zileuton and one on placebo. Of the four patients taking zileuton who had ALT values greater than or equal to 2x ULN, two had values that returned to normal while patients continued treatment and in the other two patients, resolution occurred within 20 days after discontinuation of the study drug.
About Zileuton / ZYFLO CR(TM)/ ZYFLO(R)
Zileuton inhibits 5-lipoxygenase (5-LO), an enzyme that catalyzes the formation of leukotrienes from arachidonic acid. 5-LO is the main enzyme responsible for the production of leukotrienes, a family of inflammatory mediators that can trigger asthma symptoms, including inflammation, swelling, bronchoconstriction and mucus secretion. ZYFLO CR(TM) (zileuton) extended-release tablets and ZYFLO(R) (zileuton tablets) have a unique mechanism of action that works early in the inflammatory cascade, thus blocking all types of leukotrienes. ZYFLO CR and ZYFLO are the only FDA-approved leukotriene synthesis inhibitors for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. ZYFLO CR and ZYFLO are not indicated for use in the reversal of bronchospasm in acute asthma attacks. Therapy with ZYFLO CR and ZYFLO can be continued during acute exacerbations of asthma. ZYFLO CR uses SkyePharma PLC's (LSE: SKP) proprietary Geomatrix(R) drug delivery technology, which controls the amount and rate of drug released into the body.
The recommended dose of ZYFLO CR is two 600 mg extended-release tablets twice daily, within one hour after morning and evening meals, for a total daily dose of 2400 mg. The recommended dose of ZYFLO is one 600 mg immediate-release tablet four times a day for a total daily dose of 2400 mg.
ZYFLO CR and ZYFLO are contraindicated in patients with active liver disease or transaminase elevations greater than or equal to three times the upper limit of normal. A small percentage of patients treated with ZYFLO CR (2.5%) and ZYFLO (1.9%) in placebo-controlled trials showed an increased release of a liver enzyme known as ALT and bilirubin (an orange or yellowish pigment in bile). As a result, the level of liver enzymes in patients treated with ZYFLO CR and ZYFLO should be measured by a simple blood test. It is recommended that physicians perform this test before administering ZYFLO CR and ZYFLO and repeat the test on a regular basis while patients are on the medication. Patients taking ZYFLO CR or ZYFLO and theophylline should reduce the theophylline dose by 50%. Patients taking ZYFLO CR or ZYFLO and propranolol or warfarin should be monitored and doses adjusted as appropriate. Most common side effects associated with the use of ZYFLO CR and ZYFLO are sinusitis, nausea and pharyngolaryngeal pain and abdominal pain, upset stomach and nausea, respectively.
For full prescribing information for ZYFLO CR, please visit www.zyflocr.com or call the Company's toll free telephone number 1-866-835-8216 to request medical information.
For full prescribing information for ZYFLO, please visit www.zyflo.com or call the Company's toll free telephone number 1-866-835-8216 to request medical information.
About Critical Therapeutics
Critical Therapeutics, Inc. is developing and commercializing innovative products for respiratory, inflammatory and critical care diseases. The Company owns worldwide rights to two FDA-approved drugs for the prevention and chronic treatment of asthma in patients 12 years of age and older: twice-daily ZYFLO CR(TM) (zileuton) extended-release tablets and ZYFLO(R) (zileuton tablets). Critical Therapeutics is working to develop products for acute asthma attacks that lead patients to the emergency room and other urgent care settings. The Company also is developing therapies directed toward the body's inflammatory response. Critical Therapeutics is located in Lexington, Mass. For more information, please visit www.crtx.com.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Critical Therapeutics, Inc., including, without limitation, statements regarding possible therapeutic benefits, market acceptance and future sales of ZYFLO CR; the anticipated success of the co-promotion arrangement with DEY; the progress, timing and success of the product launch for ZYFLO CR; prospects, plans and objectives of management; and all other statements that are not purely historical in nature, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "project," "should," "will," "would" and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties relating to: our ability to successfully market and sell ZYFLO CR, including the success of our co-promotion arrangement with DEY; our ability to develop and maintain the necessary sales, marketing, distribution and manufacturing capabilities to commercialize ZYFLO CR; patient, physician and third-party payor acceptance of ZYFLO CR as a safe and effective therapeutic product; adverse side effects experienced by patients taking ZYFLO CR; our heavy dependence on the commercial success of ZYFLO CR; our ability to maintain regulatory approvals to market and sell ZYFLO CR; our ability to successfully enter into additional strategic co-promotion, collaboration or licensing transactions on favorable terms, if at all; conducting clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; our ability to obtain the substantial additional funding required to conduct our research, development and commercialization activities; our dependence on our strategic collaboration with MedImmune, Inc.; and our ability to obtain, maintain and enforce patent and other intellectual property protection for ZYFLO, ZYFLO CR, our discoveries and our drug candidates. These and other risks are described in greater detail in the "Risk Factors" section of our most recent Quarterly Report on Form 10-Q and other filings that we make with the Securities and Exchange Commission. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this release.
ZYFLO(R) is a registered trademark of Critical Therapeutics, Inc.
ZYFLO CR(TM) is a trademark of Critical Therapeutics, Inc.
Geomatrix(R) is a registered trademark of SkyePharma PLC
Source: Critical Therapeutics, Inc.
----------------------------------------------
Critical Therapeutics
Inc.
Linda S. Lennox
781-402-5708
Vice President
Investor & Media Relations
llennox@crtx.com
TGAL 5.60 Tegal Establishes The Peter J. Clarke Professor and Director of the California NanoSystems Institute at The University of California, Santa Barbara
Endowed Chair Honors Contributions by PVD and Vacuum Industry pioneer Peter Clarke, Founder Of Sputtered Films, Inc., To the Micro and Nano Technology Programs at UCSB
Jun 26, 2007 9:00:00 AM
Copyright Business Wire 2007
PETALUMA, Calif.--(BUSINESS WIRE)--
Tegal Corporation (Nasdaq: TGAL), a leading designer and manufacturer of plasma etch and deposition systems used in the production of integrated circuits, MEMS, and nanotechnology devices, announced today a gift of $350,000 to establish the Peter J. Clarke Professorship for the Director of the California NanoSystems Institute at the University of California, Santa Barbara. The gift is being made by Sputtered Films, Inc. a wholly owned subsidiary of Tegal Corporation. Professor Evelyn Hu, Director of the California NanoSystems Institute (CNSI) and Professor of Electrical Engineering and Materials in the College of Engineering at UCSB, holds the first appointment for the endowed chair, which is pending final approval by the UC Regents.
"Tegal is establishing this endowed chair in order to honor the many contributions Peter Clarke, founder of Sputtered Films, Inc., and longtime Santa Barbara resident, made to UCSB during his lifetime," said Thomas Mika, Chairman, President and CEO of Tegal Corporation. "The opportunity arose, in connection with our settlement of litigation surrounding some of Peter's most important inventions, to acknowledge his key role in developing leading edge technology in use today throughout the micro and nano fabrication industries. This contribution, made on behalf of the Board of Directors and shareholders of Tegal, recognizes Peter Clarke's pivotal role in advancing technology, his love of collaborative multidisciplinary scientific research, his deep bond with the campus, and his long and fruitful collaboration with Dr. Hu. We are proud to be able to associate the name and legacy of Peter Clarke with the work of Dr. Hu, the Directorship of CNSI, and the University of California, Santa Barbara."
Peter Joseph Clarke's contributions to the scientific community began with his important research on Penning discharge physics when he was at the General Electric Research Laboratory in Schenectady, N.Y., in parallel with his graduate studies at Union College. Peter continued his work on discharge physics and applications while at Veeco Instruments and later, independently, while conducting instrument research for Brookhaven National Laboratories. He started his own company, Sputtered Films, Inc. in 1967, to capitalize on research work he performed at night and on weekends in the basement laboratory of his family home. It was there, in the basement laboratory, that he invented the S-Gun, the world's first commercially successful magnetron sputtering device for thin film PVD.
The S-Gun provided the basis for progressively more sophisticated sputtering systems, including the commercially successful Research Turbosystem, the C-2-C Coater, the Shamrock, and the Endeavor PVD cluster tool. Magnetron sputtering is now widely used to fabricate advanced semiconductor, MEMS, High Brightness LED, magnetic data storage, and nanotechnology devices in laboratory and commercial facilities around the world.
Peter Clarke held numerous patents and authored various useful scientific articles relating to reactive sputtering. His contributions to the scientific community were singled-out when he became the 1998 recipient of both the Albert Nerken Award, by the American Vacuum Society, and the Nathaniel Sugerman Award, by the Society for Vacuum Coaters. He was also honored by his employees at Sputtered Films, Inc., who established scholarships in his name for outstanding students in the fields of Math, Science, Physics, and English, at Santa Barbara City College.
Mr. Clarke's wife, Carole Clarke, a UCSB alumna, remembers that "Pete had great enthusiasm for his work. His ability to focus on the problem at hand, and to forge ahead diligently to reach a solution was one of his greatest strengths. His efforts resulted in progress; in his company and in his field. He would be very pleased and honored, as I am pleased and honored, to know that such enthusiasm and diligence will soon be undertaken in his memory by UCSB Graduate Students under the direction of Dr. Evelyn Hu. He considered Dr. Hu a friend as well as a colleague for many years. I speak for all the Clarke family, myself, our children and their spouses, and our grandchildren, in giving our sincere thanks to UCSB, Dr. Hu, and Thomas Mika of Tegal for their cooperative effort in creating the Peter J. Clarke Professor and Director of the California Nanosystems Institute at the University of California, Santa Barbara. We wish great success for all of you."
Professor Hu recalls, "Peter Clarke was an inventor 'of the old school': an intuitive thinker, a very 'hands-on' worker, in love with technology, innovations in science and always eager to test out new ideas. When I first came to UCSB, twenty years ago, we had a few pieces of equipment that barely constituted building blocks for fabrication. Among those few building blocks was equipment that Peter made available to us through deep discounts, and often through outright donations. Peter had absolute confidence in our expertise and understanding of critical trends in device research and the accompanying nanofabrication that made that research possible. He always sought out opportunities to work with us, and to bounce ideas off us. His investment in our programs went beyond any ordinary 'financial' investment; Peter's interest in our programs, and his interest in working with us, are key factors in our successful growth and development."
Professor Hu adds "For me, though, Peter's greatest influence is the person he was; passionate about ideas, embracing new science and technology on a global scale, and developing the instrumentation that allows us to access that new science and technology. He was generous with ideas and enthusiasm, brought new inventions into the marketplace, but always, always cared about how those inventions could empower others, through their capacity to engender even newer inventions. Any faculty member appreciates so much the extra freedom that the resources of a Chair will allow - the ability to instantly act on some new research idea or add resources to a classroom. Most of all, during the time that I will hold the Chair, I consider it a tremendous honor to hold this particular Chair that honors Peter, the person he was, and the contributions he made, in particular to UCSB."
About The California NanoSystems Institute
The California NanoSystems Institute is a multidisciplinary research partnership between UCLA and UC Santa Barbara established by the state legislature and California industry in 2000 as one of the first California Institutes for Science and Innovation. By exploring the power and potential of manipulating structures molecule-by-molecule, the CNSI is on its way to creating revolutionary new materials, devices, and systems that will enhance virtually every aspect of our lives - helping to drive California's economy through innovations in medical delivery and health care, powerful new information technologies, energy efficient devices, environmental improvements, and more.
About Tegal
Tegal provides process and equipment solutions to leading edge suppliers of advanced semiconductor, MEMS, and nanotechnology devices. Incorporating unique, patented etch and deposition technologies, Tegal's system solutions are backed by over 35 years of advanced development and over 100 patents. Some examples of devices enabled by Tegal technology are energy efficient memories found in portable computers, cellphones, PDAs and RFID applications; megapixel imaging chips used in digital and cellphone cameras; power amplifiers and RF filters for portable handsets and wireless networking gear; and MEMS devices like accelerometers for automotive airbags, microfluidic control devices for ink jet printers; and laboratory-on-a-chip medical test kits.
For more information about Tegal Corporation, visit: www.tegal.com
Source: Tegal Corporation
----------------------------------------------
Tegal Corporation
Thomas Mika (President & CEO)
707-763-5600
or
The Blue Shirt Group
Rakesh Mehta
415-217-7722
Chris Danne
415-217-7722
ORNG 6.36 Transportation Resource Partners Announces Promotion
Jun 26, 2007 8:55:00 AM
Copyright Business Wire 2007
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--
Transportation Resource Partners, LP (TRP), a leading private equity firm that invests in the Transportation Industry, is pleased to announce that it has promoted David R. Mitchell to Managing Director.
Mr. Mitchell joined TRP as a Principal in 2002. Prior to joining TRP, he was a Partner of a growth consulting and financial advisory firm, a Senior Manager with Deloitte Consulting in the automotive and manufacturing practice, and a Senior Consultant with Accenture.
Jim Hislop, Managing Director of TRP said, "Through his hard work and leadership capabilities, Dave has been a key contributor to the success of TRP." Added Rich Peters, Managing Director of TRP, "Dave has consistently performed at a very high level and we are pleased to recognize his strong contributions to our success through this promotion."
Mr. Mitchell holds a BS degree in Chemical Engineering from the University of Notre Dame and an MBA from the Stanford University Graduate School of Business. He currently serves as Chairman of the Board of QEK Global Solutions and is a Director of National Powersport Auctions, HomeDirect, Inc., Smith System Driver Improvement Institute, Inc., and Orange 21 Inc. (NASDAQ:ORNG). Mr. Mitchell, his wife and six children reside in Birmingham, MI.
Transportation Resource Partners, LP is a $265 million private equity fund that makes investments in growth-oriented companies operating in the Transportation and Transportation Services Industries. TRP's philosophy is to identify attractive investment situations where it can work in partnership with management to support growth. TRP's principals have extensive operating and investing experience in the Transportation Industry. TRP, along with its predecessor fund, Penske Capital Partners, has been responsible for managing over $600 million of equity capital. For more information on TRP please visit www.trpfund.com.
Source: Transportation Resource Partners, LP
----------------------------------------------
Transportation Resource Partners
Richard J. Peters
Managing Director
248-648-2100
James A. Hislop
Managing Director
201-325-3093
MITI 2.40 Publication Confirms that EpCAM, the Target for Two of Micromet's Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
Jun 26, 2007 8:30:00 AM
BETHESDA, Md., June 26 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, announced that a study published recently in the Proceedings of the National Academy of Sciences (1) supports the findings of several other studies that EpCAM (CD326), which is used as the target for Micromet's product candidates adecatumumab (MT201) and MT110, may be suitable as a target for eradication of so called "cancer stem cells" (CSCs). The other studies showed that CSCs from colon (2), breast (3), pancreatic (4) and prostate (5) cancers all express high levels of EpCAM, which, according to these studies, makes these cells particularly capable of causing tumors.
CSCs constitute a small percentage of tumor cells that have the potential to self-renew and to permanently repopulate a tumor with new cancer cells. CSCs appear to be resistant to various chemotherapies, which may be one of the key reasons why most current therapies cannot cure cancer through elimination of all tumor cells (6). Micromet scientists believe that the findings of EpCAM expression by CSCs in many cancers and of EpCAM being a frequently and highly expressed tumor-associated antigen (7, 8), supports Micromet's use of EpCAM for targeted therapeutics.
EpCAM is the target for Micromet's clinical-stage product candidate adecatumumab (MT201), a fully human monoclonal antibody being co-developed with Merck Serono. In addition, Micromet's BiTE(R) product candidate MT110, an anti-EpCAM/CD3-bispecific antibody construct, is currently in late preclinical development. Both product candidates are designed to recognize EpCAM- expressing cancer cells and to instruct cytotoxic cells of the immune system to eliminate such cancer cells.
"The 'seek and destroy' mechanism of our EpCAM-directed therapeutic drug candidates may be capable of finding and eradicating cancer stem cells in various indications," commented Patrick Baeuerle, Ph.D., Micromet's Chief Scientific Officer. "In addition, EpCAM is also expressed on the progeny of cancer stem cells, which may lead to a reduction of tumor mass by these drugs alone or by combining them with standard therapies."
References
1 Dalerba P, Dylla SJ, Park I-K et al. Phenotypic characterization of
human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007;
104:10158-63
2 Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and
expansion of human colon-cancer-initiating cells. Nature 2007;
445: 111-15
3 Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective
identification of tumorigenic breast cancer cells. Proc Natl Acad Sci
USA 2003; 100: 3983-88
4 Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer
stem cells. Cancer Res 2007; 67: 1030-7
5 Collins AT, Berry PA, Hyde C et al. Prospective identification of
tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51
6 Pan CX, Zhu W, Cheng L. Implications of cancer stem cells in the
treatment of cancer. Future Oncol 2006; 2: 723-31
7 Baeuerle PA, Gires 0. EpCAM (CD326) finding its role in cancer. Brit J
Cancer 2007; 96: 417-23
8 Went P, Vasei M, Bubendorf L et al. Frequent high-level expression of
the immunotherapeutic target Ep-CAM in colon, stomach, prostate and
lung cancers. Br J Cancer 2006; 94: 128-135
About Micromet, Inc. (www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. MT103/MEDI-538, which is the first product candidate based on Micromet's novel BiTE(R) product development platform, is being evaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. The BiTE product development platform is based on a unique, antibody-based format that leverages the cytotoxic potential of T cells, widely recognized as the most powerful 'killer cells' of the human immune system. Adecatumumab (MT201), a recombinant human monoclonal antibody which targets EpCAM expressing tumors, has completed two phase 2a clinical trials, one in patients with breast cancer and the other in patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. Micromet has established collaborations with MedImmune, Inc. for MT103/MEDI-538, Merck Serono for adecatumumab (MT201) and Nycomed for MT203.
Forward-Looking Statements
This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the intended utilization of product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research, discovery of new product candidates, and clinical trials, and partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risks associated with regulatory processes, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for future revenues under the terms of its existing collaboration agreements, and for further pre-clinical and clinical studies, development and commercialization of product candidates. You are urged to consider statements that include the words "appear," "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in Micromet's periodic reports and other filings with the SEC, including the "Risk Factors" sections of such reports.
Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Micromet, Inc.
----------------------------------------------
Chris Schnittker
SVP & CFO of Micromet
Inc.
+1-240-752-1421
christopher.schnittker@micromet-inc.com; or Investors
Susan Noonan
+1-212-966-3650
susan@sanoonan.com
or Media
Pat Garrison
+1-917-322-2567
pgarrison@rxir.com
both for Micromet
Inc.
DDDC 1.35 deltathree's Hosted Consumer VoIP Solution Adds New Payment Capabilities
Service Providers Gain Higher Level of Business Development Support through New Payment Methods of deltathree's Hosted Consumer VoIP Solution
Jun 26, 2007 8:30:00 AM
NEW YORK, June 26 /PRNewswire-FirstCall/ -- deltathree, Inc. (Nasdaq: DDDC), a leading provider of SIP-based Voice over Internet Protocol (VoIP) solutions for service providers and consumers worldwide, today announced that its Hosted Consumer VoIP Solution has enhanced its payment method component to provide further support to service providers in developing their business domestically and abroad. deltathree's Hosted Consumer VoIP Solution now provides additional payment methods and services, including multi-currency payments, electronic check, European Direct Debit and advanced Paypal capabilities. With these new enhancements, service providers are able to further expand their businesses and reach new markets worldwide.
"In our continuing commitment to innovate our service for the market, deltathree is thrilled to offer yet more ways for our Hosted Consumer VoIP Solution to support the business expansion of service providers," stated Gary Coben, deltathree's Director, Hosted Consumer VoIP Solution. "These added payment methods give service providers a new convenience for their customers and in doing so, a compelling opportunity for business growth."
deltathree's Hosted Consumer VoIP Solution is a comprehensive, customizable turnkey solution for service providers looking to launch their own VoIP offering with minimal investment and rapid deployment. Enhanced with new payment methods, the Hosted Consumer VoIP Solution allows service providers to offer innovative VoIP service both locally and overseas with seamless payment options so they can experience development opportunities worldwide. With the ability to receive payments in various currencies, service providers can more easily chart out plans of international expansion. Electronic check and European Direct Debit payment capabilities present service providers with a broader customer reach. Through the Hosted Consumer VoIP Solution, service providers can also now accept Paypal payments in various currencies and experience automated Paypal payment processes.
These new payment methods have recently been implemented by joip, deltathree's newly formed consumer group that powers the VoIP service of Panasonic's new GLOBARANGE hybrid landline/VoIP phones. GLOBARANGE phone owners automatically become part of the global joip community, where members can call each other around the world for free, and enjoy a wide variety of advanced features and services. joip's global growth will be supported by these enhanced payment methods as they will allow for consumers around the world to purchase joip's unique, affordable features in ways and currencies suitable to them. joip enabled GLOBARANGE phones will be available this summer in the United States, Canada, Brazil, Mexico, Australia, Hong Kong, the United Kingdom, Ireland, Spain, Germany, Austria and Russia.
For over a decade deltathree has been recognized as a global innovator of VoIP products, applications and infrastructure. deltathree's customized solutions enable companies to provide premier VoIP products to their consumers worldwide.
About deltathree
Founded in 1996, deltathree, Inc. is a leading provider of integrated Voice over Internet Protocol (VoIP) telephony services, products, hosted solutions and infrastructure. deltathree offers high quality Internet telephony solutions that are viable and cost-effective alternatives to traditional telephone services. Supporting hundreds of thousands of active users around the world, deltathree serves customers through its two primary distribution channels: the Service Provider / Reseller channel and the direct- to-consumer channel. deltathree's advanced solutions offer service providers and resellers a full spectrum of private label VoIP products and services, as well as a back-office suite of services. Utilizing advanced Session Initiation Protocol (SIP) technology, deltathree provides all the components to support a complete VoIP service deployment. deltathree's Consumer Group consists of the award-winning iConnectHere direct-to-consumer offering and joip, the newly formed consumer brand that powers the VoIP service of Panasonic's GLOBARANGE hybrid phone.
For more information about deltathree, please visit: www.deltathree.com.
SOURCE deltathree
----------------------------------------------
media
Susan Park
deltathree
Inc.
+1-212-500-4836
pr@deltathree.com; investors
Erik Knettel
The Global Consulting Group
+1-646-284-9415
ir@deltathree.com
SCLD 1.37 SteelCloud Receives Blade Server System Order From Major Financial Institution for Approximately $200,000
Jun 26, 2007 8:30:00 AM
HERNDON, Va., June 26 /PRNewswire-FirstCall/ -- SteelCloud, Inc. (Nasdaq: SCLD), a leading engineering and manufacturing integrator of network centric and embedded computing solutions, today announced it has received an approximate $200,000 order for an Intel(R) based blade server system and related IT services from one of the nation's leading financial institutions. The contract calls for SteelCloud to provide the institution with a specially configured, high-availability datacenter server with a wide array of technical services, including: deployment, testing, and warranty support.
"SteelCloud blade systems provide the speed and capacity necessary to drive high-end computing," said Clifton W. Sink, SteelCloud President & CEO. "Through the use of next-generation technology, our blade platforms usher datacenter operations into a new era - alleviating floor space constraints and boosting performance."
Designed with the client's required specifications, the platform was specially configured to provide energy efficiency cost savings and optimized performance. The system utilizes a unique design of ultra-thin computers (blades) sharing centralized resources, such as power supplies, fans and network switches in a single chassis. This design feature affords reduced life-cycle costs and increased scalability, allowing the client to expand capability without increasing complexity.
Installation of the system will begin in late June and will be completed by the end of the company's fiscal 3rd Quarter, which ends July 31, 2007.
About SteelCloud
SteelCloud is an engineering and manufacturing integrator specializing in network centric and embedded computing solutions for the federal government and independent software vendors. The Company designs and manufactures specialized servers and appliances for federal integrators, software vendors and volume users. The Company's ISO 9001:2000 certified Quality Management System provides procedures for continuous quality improvement in all aspects of its business. Over its 20-year history, SteelCloud has won numerous awards for technical excellence and customer satisfaction. SteelCloud can be reached at 703-674-5500. Additional information is available at www.steelcloud.com. Email: info@steelcloud.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward looking statements that involve a number of risks and uncertainties. It is possible that the assumptions made by management are not necessarily the most likely and may not materialize. In addition, other important factors that could cause actual results to differ materially include the following: business conditions and the amount of growth in the computer industry and general economy; competitive factors; ability to attract and retain personnel, including key sales and management personnel; the price of the Company's stock; and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-K and its quarterly reports on Forms 10-Q; and any reports on Form 8K. SteelCloud takes no obligation to update or correct forward-looking statements.
SOURCE SteelCloud, Inc.
----------------------------------------------
Isha Yilla of SteelCloud
Inc.
+1-703-674-5598
iyilla@steelcloud.com
uqm 4.19 UQM Technologies Receives Follow-On Contract From the U.S. Army to Continue Development of Advanced Vehicle Propulsion Motor
Jun 26, 2007 8:30:00 AM
FREDERICK, Colo., June 26 /PRNewswire-FirstCall/ -- UQM TECHNOLOGIES, INC. (Amex: UQM), a developer of alternative energy technologies, announced today that it has received a follow-on contract from the U.S. Army's Tank - Automotive and Armaments Command (TACOM) to continue the development of an advanced vehicle propulsion motor for application as a wheel mounted electric propulsion system. The ten month development effort will focus on refinements to the assembly process and design improvements to the proprietary permanent magnet electric concept motor that has demonstrated the potential to triple the torque capability of existing UQM(R) propulsion motors. Army funding for the cost-share project is $244,608 or 77 percent of the total effort.
"The proof of concept motor built and tested in the initial phase of this program validated the enhanced performance capability of this new proprietary propulsion system design. This contract will allow us to develop a number of design enhancements to the proof-of-concept propulsion system which we believe will lead to improved performance and ease of construction. This program is focused on expanding the ability of our permanent magnet propulsion motors to deliver higher levels of torque and power in a small package which is critical to the success of wheel motors for large military vehicles that are candidates for hybrid electric propulsion," said William G. Rankin, UQM Technologies' President and Chief Executive Officer. "We expect through this development program and our other ongoing development activities, to continue to expand the performance capabilities of our proprietary permanent magnet propulsion systems technology to meet this industry requirement."
UQM Technologies, Inc. is a developer and manufacturer of power dense, high efficiency electric motors, generators and power electronic controllers for the automotive, aerospace, medical, military and industrial markets. A major emphasis of the Company is developing products for the alternative energy technologies sector including propulsion systems for electric, hybrid electric, plug-in hybrid electric and fuel cell electric vehicles, under-the- hood power accessories and other vehicle auxiliaries and distributed power generation applications. The Company's headquarters, engineering and product development center, and motor manufacturing operation are located in Frederick, Colorado. For more information on the Company, please visit its worldwide website at http://www.uqm.com.
This Release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These statements appear in a number of places in this Release and include statements regarding our plans, beliefs or current expectations, including those plans, beliefs and expectations of our officers and directors with respect to, among other things the development of markets for our products and the adequacy of our cash balances and liquidity to meet future operating needs. Important Risk Factors that could cause actual results to differ from those contained in the forward- looking statements are contained in our Form 10-K filed May 17, 2007, which is available through our website at http://www.uqm.com or at http://www.sec.gov.
SOURCE UQM Technologies, Inc.
----------------------------------------------
John Baldiserra of BPC Financial Marketing
+1-800-368-1217
or Donald A. French of UQM Technologies
Inc.
+1-303-278-2002
LBIX 4.04 Photo Release -- Leading Brands, Inc. Announces Multi-Year Sponsorship Agreement Between STOKED Energy Drink and Video Game Champions Team EG
Jun 26, 2007 8:30:00 AM
2007 PrimeNewswire, Inc.
VANCOUVER, B.C., June 26, 2007 (PRIME NEWSWIRE) -- Leading Brands, Inc. (Nasdaq:LBIX), North America's only fully integrated healthy beverage company, is pleased to announce a multi-year sponsorship agreement between long-time video game champions Team EG and STOKED(tm) Energy Drinks.
A photo accompanying this release is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3870
Team EG is comprised of 20 of the World's top video gamers. Established in 1999, Team EG is one of the most recognizable brands in the fast growing, competitive video game industry. They are the undisputed Canadian champions in Counter-Strike(tm), Quake 4(tm) and Halo 2(tm). Their Counter-Strike(tm), Quake 4(tm) and World of Warcraft(tm) teams rank consistently in the top 3 in their respective fields in North America. Find out more about Team EG at www.myeg.ca.
Millions of people are actively involved in the video gaming worldwide. It is one of the fastest growing activities of any kind, anywhere. According to the Entertainment Software Association, 69% of American heads of households play computer and video games. The average game player is 33 years old and has been playing games for 12 years. 38% of all gamers are women.
Through STOKED(tm) Energy's iconic and interactive website and brand, Team EG's players and accomplishments will be profiled to gamers and energy drink consumers across North America.
Team EG will represent the STOKED(tm) brand online and on tour while annihilating their competitors in events. Working together, these two world-class brands will share a common goal: global recognition and undisputed industry dominance.
Leading Brands Chairman and CEO, Ralph McRae said: "Team EG will be an important aspect of our launch of STOKED(tm) Energy Drinks. They have had long standing success in an industry that is really still in its early stages. They have a proven and consistent record of success. As a Premium sponsor, STOKED(tm) will have a constant presence with Team EG and its members. We also hope to be able to bring added recognition to their continuing efforts to be the best at their craft in the World."
Leading Brands will continue to provide operational updates in its monthly newsletter on the first of most months, posted at www.LBIX.com.
About Leading Brands, Inc.
Leading Brands, Inc. (Nasdaq:LBIX) is North America's only fully integrated healthy beverage company. Leading Brands creates, designs, bottles, distributes and markets its own proprietary premium beverage brands such as TrueBlue(r) Blueberry Juice, LiteBlue(r) Blueberry Juice, TREK(r) Natural Sports Drinks, NITRO(r) Energy Drinks, STOKED(tm) Energy Drinks, INFINITE Health(tm) Water and Caesar's(r) Cocktails via its unique Integrated Distribution System (IDS)(tm), which involves the Company finding the best and most cost-effective route to market. The Company strives to use the best natural ingredients hence its mantra: Better Ingredients -- Better Brands.
About Team EG
Firmly embedded in the evolution of eSports worldwide, Team EG has been competing for over 5 years, making it one of the most established professional gaming organizations in the world. They continue to dominate on the world stage as the undisputed Canadian champions and ranked in North America's top 3; having swept every major Canadian event since their inception. Team EG's unique combination of talent, stability and professionalism allows them to serve as ambassadors of both competitive video gaming and STOKED(tm) Energy.
Safe Harbor.
Certain information contained in this press release includes forward-looking statements. Words such as "believe", "expect," "will," or comparable terms, are intended to identify forward-looking statements concerning the Company's expectations, beliefs, intentions, plans, objectives, future events or performance and other developments. All forward-looking statements included in this press release are based on information available to the Company on the date hereof. Such statements speak only as of the date hereof. Important factors that could cause actual results to differ materially from the Company's estimations and projections are disclosed in the Company's securities filings and include, but are not limited to, the following: general economic conditions, weather conditions, changing beverage consumption trends, pricing, availability of raw materials, economic uncertainties (including currency exchange rates), government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other risk factors described from time to time in securities reports filed by Leading Brands, Inc.
We Build Brands(tm)
This news release is available at www.LBIX.com
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
CONTACT: Leading Brands, Inc.
(604) 685-5200
info@LBIX.com
PLUS 9.44 ePlus Announces NASDAQ Board of Directors Grants Stay
Jun 26, 2007 8:30:00 AM
Copyright Business Wire 2007
HERNDON, Va.--(BUSINESS WIRE)--
ePlus inc. (Nasdaq NGM: PLUS) announced today that it received a letter from the Board of Directors of The NASDAQ Stock Market LLC (the "Nasdaq Board") on June 25, 2007. The Nasdaq Board, pursuant to its discretionary authority under Marketplace Rule 4809, has called for review the May 10, 2007 decision of the Nasdaq Listing and Hearing Review Council (the "Listing Council") regarding the Company. The Nasdaq Board has also determined to stay the Listing Council's decision to suspend the Company's securities from trading, pending consideration by the Nasdaq Board in July 2007. Accordingly, the Company's securities will not be delisted from the Nasdaq Global Market if it is unable to file its late annual and quarterly reports on or before July 5, 2007, as previously announced, pending further review by the Nasdaq Board.
As previously reported by ePlus, it received a letter from the Listing Council on May 10, 2007, granting ePlus an extension until July 5, 2007 to file its late annual and quarterly reports with the Securities and Exchange Commission ("SEC").
The Company has been diligently working to resolve issues related to accounting for stock options granted since its initial public offering in 1996, which is the sole reason underlying its delay in filing its annual and quarterly reports. In this regard, the Company has been reviewing accounting guidance regarding stock option grants recently published by the accounting staff of the SEC, and has not yet determined the amount of such charges or the resulting tax and accounting impact. The Company's determination of the amount of such stock-based compensation expense is being finalized and is being reviewed by its independent auditors. The Company plans to file its Annual Report on Form 10-K for the year ended March 31, 2006 and its Quarterly Reports on Form 10-Q for the quarters ended June 30, 2006, September 30, 2006 and December 31, 2006 as soon as practicable after the resolution of the previously disclosed matters.
ePlus has previously issued several press releases and filed several reports with the SEC including reports on Form 8-K, and investors are encouraged to read these in their entirety for discussion of the delay in its financial statements filings.
About ePlus inc.
ePlus empowers customers to maximize productivity, efficiency, and cost savings through the best people, practices, and knowledge in the technology industry. By providing access to world-class IT products and services, top level manufacturer certifications, flexible lease financing, and patented software, ePlus delivers the choices and tools for organizations to optimize their IT infrastructure and supply chain processes. Founded in 1990, ePlus has more than 650 associates in 30+ offices serving more than 2,500 customers. The company is headquartered in Herndon, VA. For more information, visit www.eplus.com, call 888-482-1122, or email info@eplus.com.
ePlus(R) and ePlus Enterprise Cost Management(R), and/or other ePlus products referenced herein are either registered trademarks or trademarks of ePlus inc. in the United States and/or other countries.
Statements in this press release, which are not historical facts, may be deemed to be "forward-looking statements". Actual and anticipated future results may vary due to certain risks and uncertainties, including, without limitation, the final determination of the impact of the restatement described above; the results of the Audit Committee's investigation; the Company's review, restatement and filing its previously issued financial statements and its assessment of the effectiveness of disclosure controls and procedures and internal controls; the Company's failure to regain compliance within any extension period that may be granted by the Nasdaq Board, in which case the Company's common stock would be delisted from the Nasdaq Global Market; the effects of any required restatement adjustments to previously issued financial statements and possible material weaknesses in internal control over financial reporting; the effects of any lawsuits or governmental investigations alleging, among other things, violations of federal securities laws, by the Company or any of its directors or executive officers; the existence of demand for, and acceptance of, our services; our ability to hire and retain sufficient personnel; our ability to protect our intellectual property; the creditworthiness of our customers; the unknown duration of the stay granted by the Nasdaq Board; our ability to raise capital and obtain non-recourse financing for our transactions; our ability to realize our investment in leased equipment; our ability to reserve adequately for credit losses; fluctuations in our operating results; our reliance on our management team; and other risks or uncertainties detailed in our Securities and Exchange Commission filings.
All information set forth in this release and its attachments is as of June 26, 2007. ePlus inc. undertakes no duty to update this information. More information about potential factors that could affect ePlus inc.'s business and financial results is included in the Company's Annual Report on Form 10-K for the fiscal years ended March 31, 2005 and March 31, 2004, the Quarterly Report on Form 10-Q for the quarters ended June 30, 2005, September 30, 2005, and December 31, 2005 under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," which are on file with the SEC and available at the SEC's website at http://www.sec.gov/.
Source: ePlus inc.
----------------------------------------------
ePlus inc.
Kleyton L. Parkhurst
SVP
703-984-8150
kparkhurst@eplus.com
WSTM 1.04 Workstream Signs Multi-Million Dollar, Multi-Year OEM Contract
Jun 26, 2007 8:30:00 AM
Copyright Business Wire 2007
BURLINGAME, Calif.--(BUSINESS WIRE)--
Workstream Inc. (NASDAQ: WSTM), a leading provider of On-Demand Human Capital Management (HCM) including compensation, performance and talent management solutions, today announced it has signed a significant multi-year OEM agreement during Workstream's fiscal Q4 2007. This agreement will embed a key Workstream technology in the OEM company's on-demand benefits management offerings. The overall contract is valued at $2,000,000 with revenue to be spread over the next two years.
"Our end-to-end integrated suite of Talent Management technologies positions us extremely well to be a partner of choice for Systems Integrators, Human Resources Outsourcers (HRO) and Business Process Outsourcers (BPO) providing Workstream opportunities to participate in larger multi-year deals worldwide," said Deepak Gupta, President and CEO of Workstream.
"This type of agreement demonstrates the strength of the Workstream technology and signals a renewed effort by Workstream to leverage partnerships to accelerate revenue growth and increase market penetration of our solutions," said Kevin Dobbs, Senior Vice President of Business Development at Workstream. "Workstream can address our partner's needs today for integrated, multi-lingual, multi-national, pay-for-performance, Talent Management solutions to the Global 2000."
About Workstream
Workstream provides on-demand compensation, performance and talent management solutions and services that help companies manage the entire employee lifecycle - from recruitment to retirement. Workstream's TalentCenter provides a unified view of all Workstream products and services including Recruitment, Performance, Compensation, Development and Transition. Access to TalentCenter is offered on a monthly subscription basis under an on-demand software delivery model to help companies build high performing workforces, while controlling costs. With offices across North America, Workstream services customers including Chevron, The Gap, Home Depot, Kaiser Permanente, Motorola, Nordstrom, VISA and Wells Fargo. For more information visit www.workstreaminc.com or call toll free 1-866-470-WORK.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Workstream's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inability to grow our client base and revenue because of the number of competitors and the variety of sources of competition we face; client attrition; inability to offer services that are superior and cost effective when compared to the services being offered by our competitors; inability to further identify, develop and achieve success for new products, services and technologies; increased competition and its effect on pricing, spending, third-party relationships and revenues; as well as the inability to enter into successful strategic relationships and other risks detailed from time to time in filings with the Securities and Exchange Commission.
Source: Workstream Inc.
----------------------------------------------
Workstream
Stacey Virgo
1-866-953-8800
Ext. 715
stacey.virgo@workstreaminc.com
CYTR 3.39 CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Dmitry Samarsky, Ph.D., as Vice President of Technology Development
Engages an Opinion Leader in the Field of RNAi
Jun 26, 2007 8:30:00 AM
Copyright Business Wire 2007
LOS ANGELES--(BUSINESS WIRE)--
CytRx Corporation's (NASDAQ:CYTR) majority-owned subsidiary, RXi Pharmaceuticals Corporation (RXi) today announced that Dmitry Samarsky, Ph.D., has joined RXi as Vice President of Technology Development. Dr. Samarsky has authored one dozen review articles and book chapters in the field of RNAi and is routinely quoted in major publications including Nature, Science and Fortune magazines. Over the past five years, he has presented at and served as an advisor for numerous academic and industry trade RNAi conferences.
"Dr. Samarsky brings RXi unmatched experience in the development and licensing of RNAi technologies," said Tod Woolf, Ph.D., RXi's President and CEO. "Dr. Samarsky will lead efforts to expand our RNAi-based therapeutics platform and promote our leading programs to major biotechnology and pharmaceutical companies."
Most recently, Dr. Samarsky served as Director of Technology Development at Dharmacon, Inc., one of the world's leading RNAi technology providers, where his team was responsible for promoting Dharmacon's RNAi program worldwide. In addition, he established and led an RNAi applications laboratory. From 2003 to 2005, Dr. Samarsky served as Business Development Manager at Invitrogen Corporation, a world-leading biomedical research manufacturing company, where he focused on promoting RNAi and other genomics technologies. From 2001 to 2003, Dr. Samarsky worked in business development at the RNAi company Sequitur, Inc., playing a critical role in that firm's acquisition by Invitrogen.
Dr. Samarsky earned a Ph.D. in biochemistry and molecular biology from the University of Massachusetts, Amherst, in 1998. From 1998 to 2001 he was the H. Arthur Smith Fellow for Cancer Research at the laboratory of Dr. Michael Green, the Howard Hughes Medical Institute investigator at the University of Massachusetts Medical School.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company owns three clinical-stage compounds based on its small molecule "molecular chaperone" co-induction technology. In September 2006, CytRx announced that arimoclomol was shown to be safe and well tolerated at all three doses tested in its Phase IIa clinical trial in patients with ALS. The Company expects to announce results of its completed open-label extension trial this week. The Company plans to enter a Phase IIb clinical trial with arimoclomol in ALS in the second half of 2007, subject to U.S. Food and Drug Administration (FDA) clearance. The FDA has granted Fast Track designation and Orphan Drug status to arimoclomol for the treatment of ALS and has also been granted orphan medicinal product status for the treatment of ALS by the European Commission. The Company has announced plans to commence a Phase II clinical trial for arimoclomol in stroke recovery in the first half of 2008, subject to FDA clearance. The Company has also announced plans to commence a Phase II clinical trial with its next drug candidate, iroxanadine, for diabetic foot ulcers in the first half of 2008, subject to FDA clearance. In addition, the Company plans to open a research and development facility in San Diego in the third quarter of 2007. For more information on the Company, visit www.cytrx.com.
About RXi Pharmaceuticals Corporation
Worcester, Massachusetts-based RXi Pharmaceuticals Corporation, a majority-owned subsidiary of CytRx, is a biopharmaceutical research and development company that focuses on developing RNAi-based therapeutics for the treatment of human disease. RXi's initial focus is on neurodegenerative diseases, oncology, type 2 diabetes and obesity. RXi has licenses to a diverse series of early patents and patent applications that were filed from 1998 to 2006 in the areas of RNAi target sequences, RNAi chemistry and RNAi delivery. The Company was founded by CytRx and RNAi pioneers Craig Mello, Ph.D., 2006 Nobel Laureate for discovering RNAi and inventing RNAi therapeutics, Tariq M. Rana, Ph.D., inventor of fundamental technology for stabilizing RNAi and of RNAi nanotransporters, Greg Hannon, Ph.D., discoverer of RNAi mechanism (RISC) and short hairpin RNAi (shRNAi), and Michael Czech, Ph.D., a leader in the application of RNAi to diabetes and obesity. RXi's CEO, Tod Woolf, Ph.D., previously co-invented and commercialized STEALTH(TM) RNAi, one of the most widely used second-generation RNAi research products.
Forward-Looking Statements
This press release may contain forward-looking statements (statements as to matters other than historical facts) as defined in the Private Securities Litigation Reform Act of 1995 and in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward looking statements. Examples of such risks and uncertainties include, but are not limited to, RXi's need to raise significant capital to fund operations and development of its potential products, intense competition with other companies focused on RNAi and other larger companies with RNAi programs and with other existing or new therapeutic modalities, the early stage of development of RXi's technology, and the scope, timing and outcome of pre-clinical and clinical testing and regulatory review of RXi's potential products. Additional risks or uncertainties are described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.
Source: CytRx Corporation
----------------------------------------------
CytRx Corporation
CEOcast
Inc.
Dan Schustack
212-732-4300
dschustack@ceocast.com
HEB 1.31 Hemispherx Biopharma Initiates Phase IIb Trial in Australia for Ampligen as Vaccine Adjuvant for Seasonal Influenza
...Goal is to Evaluate Immune Augmentation and Possible Cross-Protection by TLR Ligand Ampligen(R)
Jun 26, 2007 8:30:00 AM
Copyright Business Wire 2007
SYDNEY, Australia--(BUSINESS WIRE)--
Hemispherx Biopharma, Inc. (AMEX: HEB) announced the initiation of a well-controlled Phase IIb trial in Australia of Ampligen(R), an experimental TLR3 ligand shown to function as an immune system activator, in combination with trivalent seasonal influenza vaccine. The trial, expected to last for several months, is occurring in Australia's winter season and focuses on populations at risk for virulent cases of influenza, especially those over the age of 60 years who may lack a robust immune system.
Recently, the Pacific region has received intensified attention by health authorities due to outbreaks of both seasonal and avian influenza and recently issued warnings by the Japanese Health Ministry on possible life-threatening side effects of the presently available front-line anti-viral therapies. New outbreaks of avian influenza have also just been reported from Vietnam.
The projected Australian clinical research on the experimental TLR3 ligand Ampligen(R) is prompted by recent exciting results from the Japanese National Institute of Infectious Diseases ("JIID") which has reported very robust immune responses in animal models when Ampligen(R) was added to either seasonal or avian influenza vaccines. The JIID has also reported a wholly new therapeutic property - strong cross-protection against mutated variant flu viruses, including avian strains - when the experimental TLR activator was co-administered with the vaccine. The JIID studies administered the Ampligen(R)/vaccine combination intranasally versus the Australian regimen's subcutaneous administration. Thirty (30) patients will be enrolled in the study which will utilize a dose of Ampligen(R) of only 2mg, or 1/200 of the dosage used in Chronic Fatigue Syndrome (CFS) studies.
The U.S. Food and Drug Administration ("FDA") and regulatory agencies worldwide have just recently announced new guidelines (see FDA.gov) for accelerated approval of influenza vaccines and adjuvants, such as TLR3 ligands. In essence, the presumption of efficacy may now be established by examining for specific antibodies in the sera of treated individuals rather than waiting for disease outbreaks and pursuing much more protracted clinical endpoints during these episodic outbreaks. To operate within these guidelines, Hemispherx has already identified qualified independent testing labs in both the U.K. and Australia to monitor subjects' immune responses. Measurements of initial immune response are expected to occur within several weeks. Human safety studies will still be required for accelerated licensure, and Hemispherx expects to contribute its large dossier on Ampligen(R), being compiled in connection with its pending NDA for CFS, to expand the safety database.
Dr. William Carter, CEO/Chairman of Hemispherx commented, "We are particularly excited to initiate these influenza vaccine clinical tests for two reasons: first, they represent a major clinical extension of the outstanding pioneering research being conducted by Dr. Hasegawa and associates at JIID on combination therapy to combat a wide range of influenza strains. Second, they may establish a new route of administration of our experimental TLR3 ligand Ampligen. If JIID results can be confirmed, health authorities would be able to co-administer Ampligen with vaccine, dramatically conserving available vaccine supplies while still accomplishing a life-saving therapeutic mission."
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(R) and the experimental therapeutics Ampligen(R) and Oragens(R). Alferon N Injection(R) is approved for a category of STD infection, and Ampligen(R) and Oragens(R) represent experimental RNA nucleic acids being developed for globally important viral diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N Injection(R)) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(R), Alferon LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications.
Source: Hemispherx Biopharma, Inc.
----------------------------------------------
Hemispherx Biopharma
Inc.
Dianne Will
518-398-6222
ir@hemispherx.net
or
CCG Investor Relations
Sean Collins
310-477-9800
Sr. Partner
SATC 1.17 SatCon Receives over $2.8 Million in New Fuel Cell Inverter Orders
Jun 26, 2007 8:30:00 AM
Copyright Business Wire 2007
BOSTON--(BUSINESS WIRE)--
SatCon Technology Corporation(R) (Nasdaq CM: SATC), a developer of power management and system architecture solutions for the alternative energy and distributed power markets today announced that it has received a purchase order in excess of $2.8 million for its PowerGate(R) inverters and electrical balance of plant equipment. The inverter power system is for use on DFC1500MA(TM) megawatt-class fuel cells designed and manufactured by FuelCell Energy, Inc. (NasdaqNM:FCEL). The DFC1500MA(TM) fuel cell currently has a nominal rating of 1.2 megawatts. Delivery of the PowerGate inverters is scheduled over the next four to nine months.
FCEL is a world leading developer, manufacturer and supplier of ultra-clean fuel cell power plants that generate electricity with higher efficiency than other distributed generation plants of similar size.
"This order represents a clear sign that fuel cell power plants are a commercial reality, and we are pleased to be supporting FuelCell Energy with its commercialization program", said Clemens van Zeyl, President of SatCon Power Systems. "SatCon is committed to FuelCell Energy's commercialization program that includes continuous improvement in costs, delivery and reliability through new packaging concepts, global sourcing and manufacturing techniques."
About PowerGate(TM) Inverters
PowerGate(TM) inverters are designed for use with alternative energy power systems to generate distributed electrical power. Distributed, alternative energy power generation is a growing trend toward the production of clean, reliable power at the point of use. Alternative energy systems can alleviate congestion on highly loaded utility electrical distribution networks and offer an alternative to power line extensions in remote areas. Many alternative energy power systems require high-power, high-reliability inverters and controls to convert the power generated to useable AC power compatible with the electric power grid.
About SatCon Technology Corporation
SatCon Technology Corporation is a developer and manufacturer of power systems utilizing power electronics, advanced controls and generators/motors for the Alternative Energy, Power Delivery, Hybrid-Electric Vehicle, and Grid Support markets. SatCon also develops and manufactures High Reliability Electronics and Advanced Power Technologies. For further information, please visit the SatCon website at www.satcon.com. SATC-G
Statements made in this document that are not historical facts or which apply prospectively are forward-looking statements that involve risks and uncertainties. These forward-looking statements are identified by the use of terms and phrases such as "will," "intends," "believes," "expects," "plans," "anticipates" and similar expressions. Investors should not rely on forward looking statements because they are subject to a variety of risks and uncertainties and other factors that could cause actual results to differ materially from the Company's expectation. Additional information concerning risk factors is contained from time to time in the Company's SEC filings. The Company expressly disclaims any obligation to update the information contained in this release.
Source: SatCon Technology Corporation(R)
----------------------------------------------
SatCon Technology Corporation(R)
Dan Gladkowski
617-897-2411
VP
Administration
TKO 1.67 EthoStream Surpasses 2,000 Properties Installed with High-Speed Internet Access
EthoStream's System is Used in over 150,000 Guest Rooms with over One Million Network Users Per Month
Jun 26, 2007 8:30:00 AM
Copyright Business Wire 2007
GERMANTOWN, Md.--(BUSINESS WIRE)--
EthoStream, LLC, a Telkonet company (AMEX:TKO), operators of one of the largest hospitality high-speed Internet access (HSIA) networks in the U.S., and a preferred or endorsed provider for some of the world's largest hotel franchisors, is now delivering broadband Internet access to over 2,000 properties, representing over 150,000 guest rooms and serving over one million network users per month.
EthoStream has developed one of the largest hospitality networks in the US based on its combination of advanced technology, outstanding support and commitment to quality service. At the core of EthoStream's solution is the Remote Management Console (RMC), which enables EthoStream's support center, as well as hotel management, to remotely monitor and manage their high-speed Internet access system in real time to ensure complete guest satisfaction. EthoStream's proactive approach to quality service ensures that each hotel guest is connected to the Internet. EthoStream works with the Internet Service Provider at each property to restore service when an outage occurs. As the only provider to publish its customer support call logs, with EthoStream, hotel management can verify how calls are being handled and can review specific calls, giving them peace of mind. EthoStream brings quality of service to a new level, being proactive in monitoring customer's HSIA service and equipment and interacting with hotel management and guests.
Jason Tienor, president and CEO of EthoStream, commented, "Our solutions are custom designed with quality of service as the number one criteria. By adopting a proactive approach to service on a day-to-day basis, our customers benefit directly. This is the philosophy that differentiates us from other service providers."
About EthoStream
EthoStream, LLC is a technology solution provider targeting the hospitality and MDU/MTU verticals. Operating one of the largest hospitality high-speed Internet access (HSIA) networks in the U.S., EthoStream is a preferred or endorsed provider for some of the world's largest hotel franchisors. Now offering solutions including VOD, VoIP, digital video surveillance, Internet connectivity and HSIA packages, EthoStream has developed the most comprehensive technology management platform available for the hospitality industry.
EthoStream has distanced itself from other providers in the hospitality HSIA field through the size of its EthoStream Hospitality Network, high quality of technology and support provided to network members, security of the network and overall guest satisfaction. Beyond claims made by competitors, as the premier hospitality HSIA provider, EthoStream has continued to lead the industry through end-to-end service and its high quality standards. To learn more about EthoStream's products, services and EthoStream Hospitality Network, please visit http://www.ethostream.com.
About Telkonet
Telkonet develops and markets technology for the high-speed transmission of secure voice, video and data communications over in-premise and shipboard electrical wiring. The revolutionary Telkonet iWire System utilizes proven powerline communications (PLC) technology to deliver commercial high-speed broadband access from an IP "platform" that is easy to deploy, reliable and cost-effective by leveraging a building's existing electrical infrastructure. Telkonet's products are designed for use in commercial and residential applications, including multi-dwelling units and the hospitality and government markets.
Applications supported by the Telkonet "platform" include but are not limited to: VoIP telephones, Internet connectivity, local area networking, video teleconferencing, IP surveillance, energy management and a host of other IT services. For more information, please visit www.telkonet.com.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential factors that could affect the Company's financial results, can be found in the Company's Registration Statement and in its Reports on Forms 8-K filed with the Securities and Exchange Commission (SEC).
Source: EthoStream, LLC
----------------------------------------------
Porter
LeVay & Rose
Inc.
Michael Porter
President
212-564-4700
mike@plrinvest.com
www.plrinvest.com
or
Rubenstein Public Relations
Adam Mazur
212-843-8073
amazur@rubensteinpr.com
OPSW 9.36 Opsware Announces OVAL Security Compatibility
Certification Ensures Compatibility and Precision of Opsware Security Policies with OVAL Information Alerts
Jun 26, 2007 8:30:00 AM
Copyright Business Wire 2007
SUNNYVALE, Calif.--(BUSINESS WIRE)--
Opsware Inc. (NASDAQ:OPSW), the leading provider of Data Center Automation software, today announced compatibility certification with Open Vulnerability and Assessment Language (OVAL), based on Opsware's ability to convert OVAL information alerts into actionable policies distributed to customers by The Opsware Network, Opsware's compliance and vulnerability subscription service.
OVAL is an international information security community standard to promote open and publicly available security content, and to standardize the transfer of this information across the entire spectrum of security tools and services. The Opsware Network supports and publishes OVAL vulnerability definitions, and within 24 hours can generally translate the vulnerability advisories into actionable policies that integrate seamlessly into the Opsware Server Automation System. This powerful and proactive approach to security enables customers to eliminate security gaps within and protect servers from outside threats that could potentially wreak havoc on a customer's business.
Opsware automates what has traditionally been a manual process for managing vulnerabilities that impact today's IT organization and that is typically sourced by individual feeds from multiple data sources. This effort is tedious, time-consuming, and can often result in a costly and compromised IT environment. Through support of the OVAL platform, Opsware leverages the power of the OVAL community to ensure a thorough, complete and accurate understanding of emerging threats and vulnerabilities that impact today's IT environments. Opsware currently supports 1,816 OVAL vulnerability definitions which cover 1,145 vulnerabilities.
"OVAL is committed to providing security experts with a common language to discuss the technical details of how to maintain consistent, secure systems," said Andrew Buttner, MITRE Senior INFOSEC Engineer and OVAL Compatibility Lead. "The OVAL Compatibility Program ensures that a wide range of tools and services can seamlessly exchange security data in OVAL's standard formats. In becoming certified OVAL Compatible, The Opsware Network and Server Automation System are advancing the state of the art in information security through transparent interoperability with other OVAL Compatible tools and services."
After downloading OVAL-based policies from The Opsware Network, the Server Automation System immediately applies the policies, saving valuable time and eliminating the need to manually build policies based on vendor-specific alerts. If vulnerability definitions are not available from the OVAL community, Opsware creates its own definitions to ensure potential vulnerabilities are addressed. The end result is a rapid assessment of vulnerability impact and a dramatic reduction in the vulnerability window.
"Opsware is proud to support OVAL, the leading open standard for security content," said Tim Howes, EVP of Research & Development and CTO at Opsware Inc. "With our OVAL-certified automation products, customers can now leverage the power of the open, community-based OVAL standard in protecting their IT environments. OVAL-described vulnerabilities can now be detected, audited, and remediated automatically, saving customers time and money, and reducing the risk to their businesses."
OVAL is one of several standards in The Security Content Automation Protocol developed by several U.S. government organizations. For more information on Opsware's work with OVAL, please visit: http://www.opsware.com/products/oval.php.
About OVAL(TM)
Open Vulnerability and Assessment Language (OVAL) is an international, information security, community standard to promote open and publicly available security content, and to standardize the transfer of this information across the entire spectrum of security tools and services. OVAL includes a language used to encode system details and an assortment of content repositories held throughout the community. The language standardizes the three main steps of the assessment process: representing the configuration information systems for testing; analyzing the system for the presence of the specified state; and reporting the results of this assessment. The repositories are collections of publicly available and open content that utilize the language.
About Opsware Inc. (NASDAQ:OPSW)
Opsware, the world's leading IT automation company, unlocks the promise of technology by accelerating IT to zero latency. The company's software, the Opsware System, automates the entire data center, from provisioning to patching, configuration to compliance and discovery to deployment, turning data center operations into a competitive advantage for business. Opsware's technology is used by hundreds of companies worldwide including banks, service providers, retailers, manufacturers and Internet companies with IT environments ranging from hundreds to tens of thousands of servers, network devices, storage devices and IT processes. For more information on Opsware Inc., please visit our Web site at www.opsware.com.
Opsware is a service mark and trademark of Opsware Inc. All other product names, service marks, and trademarks mentioned herein are trademarks of their respective owners.
Source: Opsware Inc.
----------------------------------------------
Opsware Inc.
Ken Tinsley
+1 408-212-5241 (Investors)
ktinsley@opsware.com
or
Barokas PR for Opsware Inc.
Karli Overmier
+1 206-264-8220 (Press)
karli@barokas.com
HOTJ 1.39 House of Taylor Jewelry Exceeds Order Expectations, Expands Door Count at Leading Industry Trade Shows
Jun 26, 2007 8:15:00 AM
WEST HOLLYWOOD, Calif., June 26 /PRNewswire-FirstCall/ -- House of Taylor Jewelry, Inc. (Nasdaq: HOTJ) today announced that jewelry orders from a series of recent industry trade shows, including Luxury by JCK and JCK Las Vegas, exceeded $3.0 million, more than double the value of written orders of its branded jewelry products over the prior year. Additionally, new door openings at the tradeshows accounted for a 10 percent increase bringing the company's total door count to approximately 465.
Jack Abramov, president and chief executive officer, credited the successful trade show activity to strong demand for the latest designs by Dame Elizabeth Taylor and Kathy Ireland, a larger booth and prominent positioning on "5th Avenue," a focal point at this year's JCK Las Vegas reserved for the show's preeminent brands.
"In this fiercely competitive arena where thousands of diamond and jewelry companies display their products to the trade, it is clear that the industry is moving its focus to brands and branding to differentiate their products," Abramov said. "Having existing global consumer awareness with Elizabeth Taylor and Kathy Ireland clearly gives House of Taylor Jewelry a competitive advantage over companies trying to advertise their way to a brand. We are particularly pleased that both Dame Elizabeth and Kathy showed strong support with their presence at the shows this year, further fueling our sales momentum for the year ahead."
During Luxury by JCK and JCK Las Vegas, the company introduced new couture designs inspired by Dame Elizabeth, as well as its Kathy Ireland Diamond Program, an exquisite offering of classic and refined diamond jewelry collections.
About House of Taylor Jewelry
House of Taylor Jewelry is a Los Angeles-based international jewelry company whose principal shareholders include entities owned by Dame Elizabeth Taylor and Kathy Ireland, along with members of the Abramov family. It serves fine jewelry retailers worldwide with diverse jewelry collections marketed under the brands Elizabeth(TM), House of Taylor Jewelry(TM), and Kathy Ireland Jewelry(TM) Exclusively for House of Taylor Jewelry. More information on the company can be found at www.hotj.com.
Angie Yang/Evan Pondel
PondelWilkinson, Inc.
Corporate and Investor Relations
(310) 279-5980
SOURCE House of Taylor Jewelry, Inc.
----------------------------------------------
Angie Yang or Evan Pondel
both of PondelWilkinson
Inc. Corporate and Investor Relations
+1-310-279-5980
for House of Taylor Jewelry
Inc.
OCLS 7.90 Oculus Innovative Sciences Announces Results From Anti-Inflammatory Study Using Microcyn(R) Technology
Jun 26, 2007 8:08:00 AM
Copyright Business Wire 2007
PETALUMA, Calif.--(BUSINESS WIRE)--
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) today announced that International Immunopharmacology has published results from a company-sponsored study evaluating the impact of the Microcyn(R) Technology, a super-oxidized oxychlorine compound, on degranulation and cytokine release in mast cells. A reprint of the study can be viewed online: http://www.oculusis.com/articles/mastcells.pdf.
It is well established that studies on mast cell physiology are useful in identifying possible therapeutic targets for allergic/inflammatory diseases. Inflammation, often associated with certain open wounds, can delay wound healing if not controlled.
The study explored the effects of Microcyn Technology on the activation and secretion processes of mucosal-type murine bone-marrow-derived mast cells after Fc(epsilon)RI triggering using IgE-antigen. Data compiled by the study researchers at the pharmacobiology department of Cinvestav and at the cell therapy unit at the National Institute of Rehabilitation, both in Mexico City, suggest that Microcyn(R) super-oxidized solution may inhibit the cell machinery for secretion of histamine and pro-inflammatory molecules induced by IgE-antigen receptor crosslinking in vitro.
Cells were incubated in serial dilutions of Microcyn(R) for a short period of time before being activated. The in vitro test results showed that a single application of Microcyn(R) inhibited degranulation of mast cells for up to 12 hours without affecting the cell's viability or other normal physiological processes.
The results suggest that Microcyn inhibits mast cells from releasing histamine and cytokines, which are the primary catalysts in inducing inflammation. "This is an exciting finding since it further describes Microcyn Technology's mode of action within the wound bed, which distinguishes our technology from others in the market," said Hoji Alimi, Oculus founder and CEO.
"Since Microcyn(R) interfered with the secretory pathway of mast cells without inhibiting gene expression or synthesis of proteins, it could be considered a "true" mast cell stabilizer," said Dr. Claudia Gonzalez-Espinosa, one of the paper's authors.
Dr. Andres Gutierrez, director of medical affairs for Oculus, added, "Identifying the mechanism of action of Microcyn relative to mast cells could further define novel targets in the intricate pathways that are disregulated by mast cell degranulaton." The fact that Microcyn is a pH-neutral solution is important because any potential applications would likely involve the skin and very sensitive tissues in the nose, eyes, oral cavity, lungs and peritoneal cavity.
About Mast Cells
Mast cells are present in most tissues in the vicinity of blood vessels, and are especially prominent near the boundaries between the outside world and the body's internal systems. These boundary areas include the skin, mucosa of the lungs and digestive tract, as well as in the mouth, conjunctiva and nose.
In allergic reactions, mast cells remain inactive until an allergen, such as the saliva of the mosquito or the pollen of ragweed, binds to the IgE antibody (Immunoglobulin E), which is already present on the exterior of the mast cell. Once this occurs, a chain reaction is set in motion.
When activated, a mast cell rapidly releases its characteristic granules and various hormonal mediators into the interstitium. These include preformed mediators (such as histamine), newly formed lipid mediators and pro inflammatory cytokines.
Histamine dilates blood vessels, makes them leaky, and activates the endothelium. This leads to local edema (swelling), warmth, redness, and the attraction of other inflammatory cells to the site of release. It also irritates nerve endings (leading to itching or pain). Cuteanous signs of histamine release are the "flare and wheal" reaction. The bump and redness immediately following a mosquito bite are a good example of this reaction, which occurs seconds after challenge of the mast cell by an allergen.
The allergic reaction of the mast cells is oftentimes beneficial in that it helps to prevent infection and even promote healing of injured tissues. However, problems occur when the mast cells overreact thus creating allergic and chronic inflammatory diseases.
About Oculus
Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of Microcyn Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus' platform technology, called Microcyn, is a non-irritating, small molecule oxychlorine compound that is designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.
Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan K.K. Oculus' website is www.oculusis.com.
Forward-Looking Statements
Except for historical information herein, some matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about our ability to replicate the results of the test in clinical trials, if at all, or for such trials or other tests to establish the conclusions suggested by the results of the test. These forward-looking statements are identified by the use of words such as "suggest," "could involve," "could be considered, "intended," and "designed," among others. These forward-looking statements are based on Oculus Innovative Sciences, Inc.'s current expectations. Investors are cautioned that such forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business including risks inherent in the development and commercialization of potential products, the risk that scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, the Company's future capital needs, and its ability to obtain additional funding and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the quarterly report on Form 10-Q for the quarter ended December 31, 2006 and From 10-K for the fiscal year ended March 31, 2007. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements.
Oculus and Microcyn are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and services marks are the property of their respective owners.
Source: Oculus Innovative Sciences, Inc.
----------------------------------------------
Oculus Innovative Sciences
Inc.
Dan McFadden
425-753-2105
Director of Public and Investor Relations
dmcfadden@oculusis.com
or
The Ruth Group
Sara Ephraim
646-536-7002 (Investors)
sephraim@theruthgroup.com
Jason Rando
646-536-7025 (Media)
jrando@theruthgroup.com
Janine McCargo
646-536-7033 (Media)
jmccargo@theruthgroup.com
NVGN 8.81 Novogen Reaches Settlement With Chattem on Isoflavone Patent Infringement Case
Jun 26, 2007 8:00:00 AM
SYDNEY, Australia, and NEW CANAAN, Conn., June 26 /PRNewswire-FirstCall/ - - Novogen Limited (Nasdaq: NVGN; ASX: NRT), the world leader in isoflavone research, has settled the legal action it had taken against Chattem, Inc ("Chattem") on confidential terms. The lawsuit alleged that certain menopause products sold by Chattem infringed Novogen's US patents for health supplements containing isoflavones. (U.S. Patent Nos. 6,562,380 & 6,987,098).
The Chief Executive of Novogen, Mr. Christopher Naughton, said Novogen was dedicated to the development of isoflavonoid technology, protected by intellectual property, in both the dietary supplement and prescription pharmaceutical arenas.
"Novogen has also enforced its isoflavone patent portfolio against companies such as GNC, NBTY Inc., Natural Alternatives International Inc and Swanson Health Products in the USA and Swiss Herbal, Sante Naturelle, Genuine Health and WN Pharmaceuticals in Canada in recent years, reaching settlements in those matters as well," Mr. Naughton said.
Novogen manages its international research and development programs that use the expertise and clinical research capabilities of universities and hospitals in the U.S., Australia and other key international locations.
Novogen's leading dietary supplement products are Promensil, for the relief of menopausal symptoms, and Trinovin, for prostate health. Theses brands are marketed directly by Novogen in Australia, Canada and Europe, and under license to Natrol, Inc. in the U.S.A.
About Novogen
Novogen Limited is an Australian biotechnology company that has patented isoflavone technology for the treatment and prevention of degenerative diseases and disorders. Over the past ten years, Novogen has conducted the largest and most comprehensive isoflavone clinical testing programs in the world. Novogen is involved in drug discovery and product development for disorders that are commonly associated with aging and coordinates an international clinical research and development program with external collaborators, hospitals and universities.
Novogen's investigational anti-cancer drug phenoxodiol is currently in Phase III human clinical trials in the U.S. and Australia. The rights to commercialize this drug are licensed to the Company's majority owned subsidiary, Marshall Edwards, Inc., (Nasdaq: MSHL). More information can be found at www.novogen.com and www.marshalledwardsinc.com.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
SOURCE Novogen Limited
----------------------------------------------
Christopher Naughton
Managing Director of Novogen Limited
+1-011-44 (02) 9878-0088
or David Sheon of SciWords
LLC
+1-202-518-6321
for Novogen Limited
LVLT 5.86 Level 3 Communications Sets Second Quarter 2007 Earnings Call Date
Jun 26, 2007 8:00:00 AM
BROOMFIELD, Colo., June 26 /PRNewswire-FirstCall/ -- Level 3 Communications, Inc. (Nasdaq: LVLT) will release its second quarter 2007 results on Thursday, July 26, and will host a conference call at 10 a.m. EDT.
The second quarter conference call will be broadcast live on Level 3's Web site at http://www.Level3.com. If you are unable to join the call via the Web, you may access the call at 612-288-0337. You may also e-mail questions to Investor.Relations@Level3.com.
The call will be archived and available on Level 3's Web site at http://www.level3.com/investor_relations/presentations_events/conference_calls /q0207report.html, or you may access an audio replay until 11:59 p.m. EDT on Thursday, August 9, 2007, by dialing 320-365-3844 access code 877643. For additional information please call 720-888-2502.
About Level 3 Communications
Level 3 Communications, Inc. (Nasdaq: LVLT), an international communications company, operates one of the largest Internet backbones in the world. Through its customers, Level 3 is the primary provider of Internet connectivity for millions of broadband subscribers. The company provides a comprehensive suite of services over its broadband fiber optic network including Internet Protocol (IP) services, broadband transport and infrastructure services, colocation services, voice services and voice over IP services. These services provide building blocks that enable Level 3's customers to meet their growing demands for advanced communications solutions. The company's Web address is http://www.Level3.com.
"Level 3 Communications," "Level 3" and the Level 3 Communications logo are registered service marks of Level 3 Communications, LLC in the United States and/or other countries. Any other product, service and company names herein may be trademarks or service marks of their respective owners. Level 3 services are provided by wholly owned subsidiaries of Level 3 Communications, Inc.
Forward-Looking Statement
Some of the statements that we make in this press release are forward looking in nature. These forward looking statements are not a guarantee of performance and are subject to a number of uncertainties and other factors, many of which are outside our control, which could cause actual events to differ materially from those expressed or implied by the statements. The most important factors that could prevent us from achieving our stated goals include, but are not limited to our ability to: successfully integrate acquisitions; increase the volume of traffic on our network; defend our intellectual property and proprietary rights; develop new products and services that meet customer demands and generate acceptable margins; successfully complete commercial testing of new technology and information systems to support new products and services; attract and retain qualified management and other personnel; and meet all of the terms and conditions of our debt obligations. Additional information concerning these and other important factors can be found within Level 3's filings with the Securities and Exchange Commission. Statements in this press release should be evaluated in light of these important factors.
SOURCE Level 3 Communications, Inc.
----------------------------------------------
media
Josh Howell
+1-720-888-2517
or Chris Hardman
+1-720-888-2292
or investors
Robin Grey
+1-720-888-2518
or Valerie Finberg
+1-720-888-2501
all of Level 3 Communications
Inc.
ASIA 9.68 AsiaInfo to Expand China Netcom's Broadband Billing System in Zhejiang Province
Jun 26, 2007 8:00:00 AM
BEIJING and SANTA CLARA, Calif., June 26 /Xinhua-PRNewswire-FirstCall/ -- AsiaInfo Holdings, Inc. (Nasdaq: ASIA), a leading provider of telecom software solutions and IT security products and services, today announced it has won a contract with Zhejiang Netcom, a subsidiary of China Netcom, to expand its broadband billing system.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040312/CNF002LOGO )
Zhejiang Netcom's current broadband billing system, which was first deployed by AsiaInfo in 2003, supports ADSL and Ethernet based broadband and leased line services for residential and enterprise users. Under the terms of the new agreement, AsiaInfo will expand the current system to meet subscriber growth and increased demand for new services by adding software licenses and modules, and expanding system hardware.
"The rapid growth of China's broadband market presents promising opportunities for our broadband billing solutions," said Steve Zhang, President and Chief Executive Officer of AsiaInfo. "As the leading broadband billing solution provider in the Chinese telecom market, AsiaInfo is at the forefront of developing billing technologies that provide superior performance and scalability."
AsiaInfo is the leading provider of broadband billing solutions in China. Its industry-leading AIOBS Internet Protocol (IP) Billing System is deployed at the China Netcom headquarters and its 12 provincial subsidiaries.
About AsiaInfo Holdings, Inc.
AsiaInfo Holdings, Inc. (Nasdaq: ASIA) is a leading provider of high-quality telecom software solutions and IT security products and services to some of China's largest enterprises as well as many small and medium sized companies in China. An established leader in the Chinese telecommunications industry, AsiaInfo became a prominent supplier of IT security products and services in China with the acquisition of Lenovo's non-telecom related IT services business in 2004.
Organized as a Delaware corporation, AsiaInfo began operations in the United States in 1993. The Company moved major operations to China in 1995 and played a significant role in the construction of the national backbones and provincial access networks for all of China's major national telecom carriers, including China Telecom, China Mobile, China Unicom and China Netcom. Since 1998, AsiaInfo has continued diversifying its product offerings and is now a major provider of telecom software solutions in China.
For more information about AsiaInfo, please visit http://www.asiainfo.com .
Forward-Looking Statements
The information contained in this document is as of June 26, 2007. AsiaInfo assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments.
This document contains forward-looking information about AsiaInfo's operating results and business prospects that involve substantial risks and uncertainties. You can identify these statements by the fact that they use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Among the factors that could cause actual results to differ materially are the following: government telecommunications infrastructure and budgetary policy in China; our ability to maintain our concentrated customer base; the long and variable cycles for our products and services that can cause our revenues and operating results to vary significantly from period to period; our ability to meet our working capital requirements; our ability to retain our executive officers; our ability to attract and retain skilled personnel; potential liabilities we are exposed to because we extend warranties to our customers; risks associated with cost overruns and delays; our ability to develop or acquire new products or enhancements to our software products that are marketable on a timely and cost-effective basis; our ability to adequately protect our proprietary rights; the competitive nature of the markets we operate in; political and economic policies of the Chinese government. A further list and description of these risks, uncertainties, and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and in our periodic reports on Forms 10-Q and 8-K (if any) filed with the United States Securities and Exchange Commission and available at http://www.sec.gov .
For more information, please contact:
For Investors:
Charles Zhang
AsiaInfo Technologies (China), Inc.
Tel: +86-10-8216-6039
Email: ir@asiainfo.com
For Media:
Rory Macpherson
Ogilvy Public Relations Worldwide
Tel: +86-10-8520-6553
Email: rory.macpherson@ogilvy.com
SOURCE AsiaInfo Holdings, Inc.
----------------------------------------------
Charles Zhang (Investors) of AsiaInfo Technologies (China)
Inc.
+86-10-8216-6039
or ir@asiainfo.com; Rory Macpherson (Media) of Ogilvy Public Relations Worldwide
+86-10-8520-6553
or rory.macpherson@ogilvy.com
for AsiaInfo Technologies (China)
Inc.
ATML 5.67 Atmel's ARM Based AT91SC192192CT-USB Secure Microcontroller for e-Tokens and Embedded Systems
Jun 26, 2007 8:00:00 AM
ROUSSET, France, June 26 /PRNewswire/ -- Atmel(R) Corporation (Nasdaq: ATML), announced today the availability of the AT91SC192192CT-USB, a FLASH based, ARM(R) SC100 powered, secure microcontroller. The AT91SC series is a family of low power, high-performance 32-bit RISC secure microcontroller with ROM or FLASH program memory, advanced EEPROM data memory and powerful cryptographic accelerators. These products target applications that require high computing power, high-speed communication interfaces and seamless connection to very large memories.
Based on the ARM(R) SC100 CPU, the AT91SC192192CT-USB features 192 Kbytes of FLASH program memory, 192 Kbytes of high-performance EEPROM (fast erase/write time, high endurance) and 24 Kbytes of RAM. Also included are a Full Speed USB 2.0 interface with 5 Endpoints, an SPI interface to communicate in an Embedded System environment or to connect to a NOR Flash and dedicated hardware to connect to a NAND Flash. The device is particularly well suited to build high-end secure e-Tokens and to be used in Embedded Systems where it can serve as a Security Module to prevent hardware counterfeiting, store secure data, provide authentication services, process digital rights management etc.
Fully compatible with the ROM-based AT91SC512384RCT, the AT91SC192192CT-USB also incorporates the standard ISO 7816 Smart Card and the emerging Single Wire Protocol (SWP) interfaces. This makes the AT91SC192192CT-USB a flexible FLASH alternative to its ROM sibling for Smart Card applications such as next-generation (U)SIM cards.
Eric Le Cocquen, Atmel's Embedded Systems Product Line Manager stated, "Our new AT91SC192192CT-USB combines Atmel's recognized Smart Card Chip Security, state of the art crypto and ARM(R) SC100 computing power with FLASH flexibility on a versatile platform designed to address a wide spectrum of security applications. Thanks to its rich set of interfaces and FLASH, our product can quickly be added to virtually any embedded system."
Availability and Pricing
AT90SC192192CT-USB samples are available now in a LQFP64 package. Pricing starts at US $8.84 for 10k units.
About Atmel
Atmel is a worldwide leader in the design and manufacture of microcontrollers, advanced logic, mixed-signal, nonvolatile memory and radio frequency (RF) components. Leveraging one of the industry's broadest intellectual property (IP) technology portfolios, Atmel is able to provide the electronics industry with complete system solutions focused on consumer, industrial, security, communications, computing and automotive markets.
(C) 2007 Atmel Corporation. All Rights Reserved. Atmel(R), logo and combinations thereof, and others are registered trademarks or trademarks of Atmel Corporation or its subsidiaries. ARM(R) is a registered trademark of ARM Limited. Other terms and product names may be trademarks of others.
Information:
Atmel's AT91SC192192CT product information may be retrieved at http://www.atmel.com/dyn/products/product_card.asp?part_id=4158
For further information on the SecureARM family, go to http://www.atmel.com/products/SecureARM/
Press Contacts:
Carine Bourgon, Communications Manager - Rousset
Phone: (+33) 4 42 53 60 52, Email: carine.bourgon@rfo.atmel.com
Helen Perlegos, Public Relations - USA and Asia Pacific Rim
Phone: (+1) 408 487-2963, Email: hperlegos@atmel.com
Veronique Sablereau, Corporate Communications Manager - Europe
Phone: +33 1 30 60 70 68, Fax: + 49 71 31 67 24 23
Email: veronique.sablereau@atmel.com
SOURCE Atmel Corporation
----------------------------------------------
Carine Bourgon
Communications Manager - Rousset
(+33) 4 42 53 60 52
carine.bourgon@rfo.atmel.com
or Helen Perlegos
Public Relations - USA and Asia Pacific Rim
+1-408-487-2963
hperlegos@atmel.com
or Veronique Sablereau
Corporate Communications Manager - Europe
+33 1 30 60 70 68
fax
+ 49 71 31 67 24 23
veronique.sablereau@atmel.com
all of Atmel Corporation
THRM 8.20 Thermage Introduces Lips by Thermage, a New Non-Invasive Aesthetic Procedure for Lips
Offering consumers fuller, more defined looking lips without injections
Jun 26, 2007 8:00:00 AM
HAYWARD, Calif., June 26 /PRNewswire-FirstCall/ -- Thermage, Inc. (Nasdaq: THRM) today announced the introduction of Lips by Thermage(TM), a new non-invasive procedure to help smooth and tighten skin for fuller, more defined looking lips and decreased fine lines. The procedure is the latest in a suite of procedures under the Body by Thermage(TM) umbrella and is a non-invasive alternative to the many surgical and injectable options available on the market today.
"Thermage is a great option for those patients seeking younger, fuller, more defined looking lips without having an injection," said Maxine Tabas, M.D. of Orlando, FL.
Lip treatments appear to be a sizeable market opportunity based on the growth of fillers over the past several years. According to Medical Insight, Inc., overall filler revenue grew 35% in 2006. Additionally, treatment of lips with fillers increased by approximately 20,000 procedures in 2006, according to the American Society for Aesthetic Plastic Surgery.
"Lips by Thermage is another important step for Thermage in providing our customers with the latest procedures to address their patients' needs," said Stephen J. Fanning, president and chief executive officer at Thermage. "This new procedure will provide patients with a cosmetic lip treatment option without the fear of injections or surgery."
The procedure uses a 1.5cm2 ThermaTip(TM) ST treatment tip, which is specifically designed to treat smaller areas, such as the skin above the upper lip. During clinical evaluations, patients found their lips had a fuller and more defined appearance, fine lines and wrinkles were diminished, and the skin above their lips was smoother and softer.
Dr. Tabas added, "My patients who have had this procedure no longer complain about their lipstick running and have actually found it easier to apply lip liner."
Lips by Thermage, like all Body by Thermage procedures, uses a unique monopolar capacitive radiofrequency technology to stimulate and tighten existing collagen as well as promote new collagen growth. Patients benefit from a single treatment with no downtime. Results are natural looking, subtle and improve over a period of two to six months.
About Thermage, Inc.
Thermage's innovative technology provides a unique non-invasive procedure to tighten and contour skin, greatly expanding the aesthetic applications physicians can offer to the booming "anti-aging" market. The company commercially launched its flagship ThermaCool(R) system in 2002 when it received clearance from the U.S. Food & Drug Administration. Today, the ThermaCool system is available in 80 countries; nearly 400,000 patients have been treated with Thermage and approximately 2,000 dermatologists, plastic surgeons and other cosmetic physicians are using the Thermage procedure worldwide. For more information about Thermage, call 1-510-259-7117 or log on to http://www.thermage.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, the statement concerning our belief that lip treatments represent a sizable market opportunity for the Company constitutes a forward-looking statement. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Thermage's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Thermage's business are detailed in the Company's Form 10-Q for the period ended March 31, 2007. Undue reliance should not be placed on forward-looking statements, which speaks only as of the date they are made. Thermage undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
The ThermaCool system is FDA cleared for the non-invasive treatment of wrinkles and rhytids. Treatment results may vary depending on age and skin condition.
Thermage, ThermaCool, ThermaTip, Body by Thermage and Lips by Thermage are trademarks of Thermage, Inc.
SOURCE Thermage, Inc.
----------------------------------------------
Media
Jackie Quintanilla of Edelman
+1-323-202-1053
jacqueline.quintanilla@edelman.com
or Investors
Jenifer Kirtland of EVC Group
+1-415-896-6820
jkirtland@evcgroup.com
both for Thermage
Inc.
INBP 5.18 Integrated BioPharma's Wholly Owned Subsidiary, The Organic Beverage Company, Launches Syzmo Organic Energy Drink, Its Mainstream Energy Beverages
Jun 26, 2007 8:00:00 AM
2007 PrimeNewswire, Inc.
HILLSIDE, N.J., June 26, 2007 (PRIME NEWSWIRE) -- Integrated BioPharma's (Nasdaq:INBP) wholly owned subsidiary, The Organic Beverage Company, today announced the launch of its new Syzmo(tm) flavored drinks aimed at the high-growth, convenience and on-premises mainstream energy drink category. These new offerings will be widely available in mid-July. Syzmo(tm) products are currently sold through stores and distributors such as Whole Foods and Tree of Life.
"At the same time that we roll out the new flavors, we are also presenting our new packaging for this much broader distribution channel," said Jeffrey O'Neal, President of The Organic Beverage Company.
Syzmo(tm) has been recognized as the first USDA organic energy drink in the market and is now the first and only certified Glycemic Index Tested carbonated beverage in the world.
The Organic Beverage Company has been a leader in addressing the functional beverage market with healthy, alternative beverages designed to provide consumers with choices when selecting a functional beverage. The new product designs include premium blue agave nectar, organic caffeine, a full complement of RDA vitamins, pleasing taste profiles, and, importantly, no high fructose corn syrup.
Additional information on The Organic Beverage Company and its product, Syzmo(tm), can be obtained from our website, http://www.syzmo.com or by calling (866) 637-8802.
About Integrated BioPharma, Inc. (INBP)
Integrated BioPharma, Inc. is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a GMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at http://www.ibiopharma.com
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such Statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.
CONTACT: Integrated BioPharma Inc.
Jeffrey Leach, VP
Dina Masi, CFO
d.masi@ibiopharma.com
888-319-6962
13:15 6/26/2007 HLTK 1-100 R/S **
Healthtek Inc Unclassified CWTE C'Watre International, Inc. Common Stock
13:15 6/26/2007 CWRN 1-500 R/S ** Cotton & Western Mining, Inc. Common Stock CWRM Cotton & Western Mining, Inc. New Common Stock
13:15 6/26/2007 BLYC Stock 1-500 R/S ** Bentley Commerce Corporation Common Stock BLYO Bentley Commerce Corporation New Common
6/26/2007 AZCE 1-120 R/S ** Aztec Energy Corporation Common Stock BLZE Blaze Energy Corp. Common Stock
ADL 3.80 AMDL Signs Additional New Two Year Chinese Distribution Agreement for Minimum Sales of Approximately $921,000
Jun 25, 2007 8:51:00 AM
TUSTIN, Calif., June 25 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. AMDL announced today that through its subsidiary, JJB, it has signed an agreement with YunNan KunMing YuSi Pharmaceutical Co. Ltd. (YKY) to distribute levofloxacin (100ml/bottle). This $921,000 distribution agreement will be effective in July 2007 for a term of two years. YKY is a direct affiliate to the Commission of Science Technology and Industry for National Defense.
Mr. Frank Zheng, Managing Director of JPI, stated that "this additional purchase orders puts JPI on its way to building sales in China by as much as $24 million over the next 12 month sales cycle."
Mr. Gary Dreher, CEO of AMDL, noted that "this additional purchase agreement is truly exciting and significantly enhances JPI's ability to grow its sales in the China markets."
About Jade: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.
Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc.
Mr. Paul Knopick
AMDL Investor Relations
Direct Line: 949.707.5365
Voice Mail: 714.505.4460
SOURCE AMDL, Inc.
----------------------------------------------
Mr. Paul Knopick
AMDL Investor Relations
+1-949-707-5365
voice mail
+1-714-505-4460
QD 3.19 QuadraMed Showcasing Identity Management Solutions, Part Of Its ''Denial Prevention'' Strategy, At HFMA-ANI In San Diego
Jun 25, 2007 8:47:00 AM
Copyright Business Wire 2007
RESTON, Va.--(BUSINESS WIRE)--
QuadraMed(R) Corporation (Amex:QD) today announced that the company will be demonstrating its Smart Identity Management Solutions(TM) during exhibit hall hours June 25-26, booth 1202, at the 2007 HFMA-ANI (Healthcare Financial Management Association - Annual National Institute) event in San Diego. Identity Management is the first step in analyzing propensity to pay and can have a positive effect on revenue management by decreasing claims denials.
QuadraMed Identity Management solutions enable clients to implement a pro-active approach to claims denials that for decades have had a negative impact on the financial health of provider organizations. This methodology is intended to replace previous processes that focus on denial management after payment has been refused. Instead, QuadraMed's approach is designed to help hospitals avoid billing problems before they occur.
QuadraMed received its third consecutive Best in KLAS(R) award for Acute Care Registration, Scheduling and Patient Accounting in the 2006 "Top 20 Best in KLAS Awards," while QuadraMed MPI (Master Person Index) earned the top rating for General Market Solutions in the EMPI category in the same report. QuadraMed continues to develop innovative enhancements to its revenue cycle products that provide an end-to-end solution to meet the market's demand for technology that can help ensure the current and future financial health of single facility hospitals, IDNs and multi-facility institutions.
QuadraMed M5, a new release featuring a comprehensive series of product enhancements, was announced this month. For the QuadraMed Revenue Cycle Management solution these enhancements include support for the National Provider Identifier, further upgrades to the highly acclaimed QuadraMed EDI applications, and advanced functionality for the solution's Central Business Office software. Details about this release will also be available at the QuadraMed booth.
Exhibit hall hours during HFMA-ANI on Monday, June 25 and Tuesday, June 26 are 11:45 a.m. to 2:30 p.m., and from 4:15 p.m. to 6:00 p.m. QuadraMed is a Technology Sponsor of the HFMA Patient Friendly Billing(R) Project, which promotes clear, concise, and correct patient-friendly financial communications.
For information about all QuadraMed Care-Based Revenue Cycle solutions and related services, visit www.quadramed.com or call 800.393.0278.
About QuadraMed Corporation
QuadraMed Corporation advances the success of healthcare organizations through IT solutions that leverage quality care into positive financial outcomes. Using QuadraMed's Care-Based Revenue Cycle solutions, which are designed to optimize the patient experience and leverage quality of care into payment, our clients seek to receive the proper reimbursement, in the shortest time, at the lowest administrative cost. QuadraMed delivers real-world solutions that help healthcare professionals deliver outstanding patient care with significant efficiency. Behind our products and services is a staff of 600 professionals whose experience and dedication to service have earned QuadraMed the trust and loyalty of customers at approximately 2,000 healthcare provider facilities.
Cautionary Statement on Risks Associated with QuadraMed's Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 by QuadraMed that are subject to risks and uncertainties. The words "believe," "expect," "anticipate," "intend," "plan," "estimate," "may," "should," "could," and similar expressions are intended to identify such statements. Forward-looking statements are not guarantees of future performance and are to be interpreted only as of the date on which they are made. QuadraMed undertakes no obligation to update or revise any forward-looking statement except as required by law. QuadraMed advises investors that it discusses risk factors and uncertainties that could cause QuadraMed's actual results to differ from forward-looking statements in its periodic reports filed with the Securities and Exchange Commission ("SEC"). QuadraMed's SEC filings can be accessed through the Investor Relations section of our website, www.quadramed.com, or through the SEC's EDGAR Database at www.sec.gov (QuadraMed has EDGAR CIK No. 0001018833).
QuadraMed is a registered trademark of QuadraMed Corporation. Care-Based Revenue Cycle and Smart Identity Management Solutions are trademarks of QuadraMed Corporation. All other trademarks are the property of their respective holders. Information from the "Top 20 Year-End Best in KLAS Awards" is (C)2006 KLAS Enterprises, LLC, www.healthcomputing.com. All Rights Reserved.
Source: QuadraMed Corporation
----------------------------------------------
QuadraMed Corporation
Brooke Kane
Marketing Manager
703-989-7020
press@quadramed.com
or
Investor Relations
703-742-5393
InvestorRelations@quadramed.com
KERX 10.07 Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
Presentation Scheduled for Wednesday, June 27th at 1:00pm ET
Jun 25, 2007 8:45:00 AM
NEW YORK, June 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that I. Craig Henderson, MD, the Company's President, is scheduled to present at the Jefferies & Co. Healthcare Conference being held in New York City. Dr. Henderson's presentation will take place on Wednesday, June 27th at 1:00 pm ET.
Dr. Henderson's presentation will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end- stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in- class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
KERYX CONTACT:
Ronald C. Renaud Jr.
Chief Financial Officer, Treasurer
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
SOURCE Keryx Biopharmaceuticals, Inc.
----------------------------------------------
Ronald C. Renaud Jr.
Chief Financial Officer
Treasurer of Keryx Biopharmaceuticals
Inc.
+1-212-531-5965